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In this dissertation a methodology is proposed for simultaneously evaluating the 
population bioequivalence (PBE) of a generic drug to a pre-licensed drug, or the 
bioequivalence of two formulations of a drug using multiple correlated pharmacokinetic 
metrics. The univariate criterion that is accepted by the food and drug administration 
(FDA) for testing population bioequivalence is generalized.  
Very few approaches for testing multivariate extensions of PBE have appeared in 
the literature. One method uses the trace of the covariance matrix as a measure of total 
variability, and another uses a pooled variance instead of the reference variance. The 
former ignores the correlation between the measurements while the later is not equivalent 
  xiii 
to the criterion proposed by the FDA in the univariate case, unless the variances of the test 
and reference are identical, which reduces the PBE to the average bioequivalence. 
The confidence interval approach is used to test the multivariate population 
bioequivalence by using a parametric bootstrap method to evaluate the  1  100% 
confidence interval. The performance of the multivariate criterion is evaluated by a 
simulation study. The size and power of testing for bioequivalence using this multivariate 
criterion are evaluated in a simulation study by altering the mean differences, the 
variances, correlations between pharmacokinetic variables and sample size. A comparison 
between the two published approaches and the proposed criterion is demonstrated. Using 
nonlinear models and nonlinear mixed effects models, the multivariate population 
bioequivalence is examined. Finally, the proposed methods are illustrated by 
simultaneously testing the population bioequivalence for AUC and maxC  in two datasets. 
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1 Introduction 
 
 Bioequivalence (BE) studies are an essential component of the 
applications for approval of generic drugs or new formulations of previously licensed 
drugs submitted to the regulatory agencies. Any two drugs are deemed to have the same 
therapeutic effect if they have the same rate of absorption, the same maximum 
concentration or level of the pharmacologically active material at the site of action, and 
the same total amount available before the drug is completely excreted. This is 
considered fundamental for bioequivalence and is sometimes referred to as the 
fundamental assumption for bioequivalence (Chow and Liu, 2009).  
Bioequivalence is closely related to bioavailability (BA) in drug testing. Both are 
required by the Food and Drug Administration (FDA) for the approval of drugs, and 
therefore essential in investigational new drug applications (INDs), new drug applications 
(NDAs), abbreviated new drug applications (ANDAs), and their supplements. The FDA 
regulates BE studies and the regulations governing these studies are provided in part 320 
of 21 CFR (FDA, 2000). 
Bioavailability is defined by the FDA in 21 CRF 320.1 as: 
“The rate and extent to which the active ingredient or active moiety is absorbed from a 
drug product and becomes available at the site of action. For drug products that are not 
intended to be absorbed into the bloodstream, bioavailability may be assessed by 
measurements intended to reflect the rate and extent to which the active ingredient or 
active moiety becomes available at the site of action.”   
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Bioequivalence is defined by the FDA in 21 CRF 320.1 as: 
“The absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives 
becomes available at the site of drug action when administered at the same molar dose 
under similar conditions in an appropriately designed study.” 
Establishing bioavailability (BA) of any drug is a benchmark effort with 
comparisons between formulations and routes of admission such as oral solution, oral 
suspension, or an intravenous formulation. Whereas, demonstrating BE is usually formal 
and use comparative statistical tests that uses specific criteria for comparisons (FDA, 
2000). To license a generic drug it is essential to demonstrate that the newly proposed 
drug or formulation contains the same active pharmaceutical moiety with the same dose 
and strength and it has the same route of administration. The producer of the test 
(generic) drug should show that the release of an active substance from the test drug 
product and the subsequent absorption into the systemic circulation is similar to the 
release and absorption of the reference drug. There is a need to demonstrate that the 
bioavailability of the proposed drug is similar to that of the approved and listed drug, the 
reference drug.  To test for the similarity of the bioavailability of the two drugs, 
bioequivalence testing is required. 
1.1. Types of Bioequivalence Measures: 
1.1.1  Average Bioequivalence 
Average bioequivalence (ABE) is the most widely used measure of BE in the 
pharmaceutical industry and research. It compares between the means or averages of the 
test and reference drug distributions. Bioequivalence is concluded if the confidence 
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interval of difference between the means of the reference and the test means falls within a 
predefined range. 
This measure ignores the difference in the variance between the test and reference 
drug distributions. Ignoring the differences in the variance does not guarantee that the 
two drugs, reference and test, could be used interchangeably in terms of safety and 
efficacy. 
1.1.2  Population Bioequivalence 
Population bioequivalence (PBE) is another measure of bioequivalence that was 
proposed to evaluate prescribability of the drug. Prescribability of a drug is defined as the 
ability to get the same effect by prescribing the brand-name drug or its generic drug to a 
new patient (Chow and Liu, 2009).  As mentioned in section 1.1.1 the ABE focuses only 
on the comparison of population averages of the rates or extent of absorption and not on 
the variances of these measures. In contrast, PBE includes comparisons of both the means 
and variances of the measures. Therefore, the PBE approach assesses total variability of 
the measure in the population (Hauk and Anderson, 1992, FDA 1997). 
1.1.3  Individual Bioequivalence (IBE) 
Individual bioequivalence was proposed to evaluate switchability of two drugs. 
Switchability (Anderson, 1993; Liu and Chow, 1995) is defined as the ability to switch 
from the brand-name drug to a generic drug while guaranteeing the same efficacy and 
safety to the patient who was using the brand-name drug. It is recommended to assess 
bioequivalence within individual subjects to assess switchability. Intra-subject variances 
are included in the comparison between the test and reference drugs when assessing IBE.  
 
 17 
 
1.2. The Hypothesis of bioequivalence:  
Let  be a BE measure of interest, usually, in the case of ABE, the difference 
between the means of the pharmacokinetic parameters (PK) of the two drugs being 
compared. Let 1  and 2  be two pre-defined bioequivalent limits. Then the two-sided 
hypotheses to assess bioequivalence are: 
0 1 2 1 2: :aH or vs H           
These hypotheses can also be rewritten as two one-sided hypotheses as  
01 1 1 1: :aH vs H      
and 
02 2 2 2: :aH vs H     .
 
If both null-hypotheses are rejected at level , there is evidence of bioequivalence 
at 100(1-)% significance. If   is the difference between the average PK parameters of 
two drugs, the 100(1 – 2)% confidence interval for   could be constructed as  
     ˆ ˆ ˆ ˆˆ ˆ ˆ ˆ ˆ ˆ,
T R T RT R T R
z z                (1) 
 
where ˆ ˆT R  is the difference between the two estimated means of the PK parameter 
for drugs T and R, and ˆ ˆˆ
T R 
  is the estimated standard deviation of the difference 
between the means. Then testing the two hypotheses simultaneously is equivalent to 
comparing the confidence interval to the bioequivalence acceptance region for  1 2,    
 ˆ ˆ0.2 ,0.2R R  , where ˆR  is the estimated mean of the PK of the reference drug.  
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The estimates of the differences in the means and the 100(1 – 2)% confidence 
intervals, and the estimate of the reference mean could be obtained from any 
experimental design such as parallel or cross-over trials. 
1.3. Assessing Bioequivalence 
The goal of bioequivalence studies is to test the hypothesis that two or more drugs 
are bioequivalent in terms of PK parameters. Experiments designed to assess 
bioequivalence of drugs take a wide range of measurements of the levels of the drug in 
the blood or plasma over a period of time. The key parameters in bioequivalence testing 
are shown as part of a typical plasma concentration time profile in Figure 1 (Mehrotra 
2007). The figure shows also the minimum effective concentration (MEC) which is the 
minimum concentration to produce the desired pharmacological effect; and the maximum 
tolerable concentration (MTC) beyond which toxic and adverse events are intolerable. 
From such concentration-time data or curves several PK parameters such as the rate of 
absorption ( ak ), and ( maxT ) the time until the maximum concentration ( maxC ) is 
reached, and total available dose (area under the blood level-time curve ( AUC )) are 
either measured or estimated. 
For example, the AUC  resultant from a single dose of a drug formulation is 
commonly assessed with the linear trapezoidal method (Berger RL, 1996, Gibaldi, 1982). 
The average of two subsequent plasma-concentrations (Ci and 1Ci ) is calculated,  then 
it is multiplied by the difference between the consecutive time points ( ti  and 1ti ). The 
partial areas are then summed to produce the AUC   
 19 
 
  10 1
2
1
t
C Ci iAUC t tt i i
i
    
 
 . (2) 
The total area under the curve would be estimated as  
 0 0
ClastAUC AUC t
ke
   , (3) 
where ke  is the elimination constant, which describes the rate of reduction of the log 
plasma-concentration per unit time. This constant could be estimated as the value of the 
slope of the reduction of the log concentration by time. Thus it could be calculated using 
the elimination half-life ( 1 2t ) which is the time it takes for the concentration of the drug 
to fall to half its concentration. Suppose the concentration of the drug dropped for 1C  
measured at time 1t to its half 2C  at time 2t , then the time difference 2 1t t  is noted as 
1 2t   which is known as the half time. Then the elimination constant could be calculated 
as rate of this drop as: 
     log 2 1 log 2 1 log 1 2log 2 log 1 0.693
1 2 1 2 1 2 1 2 1 2
C C C CC C
ke
t t t t t

      
The trapezoidal formula used for AUC  is an approximation of the total area 
under the curve. The further the distance between the time points when the blood 
concentrations are measured, the larger the inaccuracy of the calculated AUC . 
Depending on the original profile of blood concentration curve, this could be an 
underestimation in some cases and an overestimation in other cases. 
maxC  is measured as the highest observed concentration. Although this measure 
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Figure 1 Typical plasma concentration time profile after oral administration 
 
 Cmax, maximum concentration; tmax, time to Cmax; AUC, area under the curve; MEC, minimum effective 
concentration; MTC, maximum tolerated concentration. 
 
rarely coincides with the true maxC  
(the estimate is biased downward), this measure is 
widely used in bioequivalence determinations. It is not unusual for plasma concentration 
profiles that reach a peak then the concentration drops, only for the concentration to peak 
again. The second peak may be higher or lower than the first peak. In these situations, the 
maxC is usually estimated as the concentration of the highest peak in profile. However, 
the first peak may be used as the estimate of maxC  when used as a measure of 
 21 
 
absorption. The maxT  
is defined as the time when maxC is observed, and similar to 
maxC , it is rarely accurate. 
The rate of absorption could be measured in two ways. The first method is based 
on the linear fit of the first few points (at least three points) from beginning of the 
concentration profile to the first peak. This absorption constant, usually noted as 0k , is 
calculated as the slope of that linear fit. The number of points chosen for this fit is based 
on the R-squares of the fits.  Other methods uses nonlinear models to estimate the 
absorption rate constant denoted as ak . These estimates of the bioequivalence parameters 
are non-model based calculations and they cannot account for the uncertainty in 
measuring the drug concentration. Alternatively, these parameters could also be estimated 
by fitting mechanistically meaningful non-linear models. 
By assumption, if the difference between the new test drug and the reference drug 
in terms of the means of these pharmacokinetic parameters are within a pre-defined 
acceptable magnitude then the drugs are deemed bioequivalent. 
1.4. Extensions considered in this dissertation 
Most of the pharmacokinetic parameters are derived from the same blood 
concentration-time profile. This makes them correlated and therefore individually testing 
each measure for BE is not optimal. Several approaches to extend the ABE methods to 
multivariate situation have been proposed (Brown, 1995; Berger and Hsu, 1996; Brown, 
1997; Munk and Pflujer, 1999; Wang, 1999; and Tamhane and Logan, 2004). However, 
for the population BE only one method has been suggested and investigated in the 
literature for the multivariate bioequivalence (Chervoneva, 2007).  However, this 
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approach is based only on the trace of the variance covariance matrix. Since the trace is 
the sum of the diagonal elements of the matrix, this approach essentially ignores the 
correlation between the pharmacokinetic measures and therefore could not be considered 
an extension of the univariate approach to the  multivariate situation.  Another method 
was suggested by Dragalin et al. (2003), in which the Kullback–Leibler divergence 
(KLD) was used to evaluate the multivariate case of IBE. They proposed an analogous 
method to be applied to evaluate the PBE. Their method was not studied, and was not 
accepted by the FDA. 
Another aspect of the bioequivalence methods that is often ignored in the 
literature is the fact that many of the pharmacokinetic measures are derived from the 
concentration-time curves and therefore there is uncertainty in the estimates. When these 
measures are based on a single compartment non-linear fit of the data it is possible to 
estimate this uncertainty and incorporate it in the BE tests. One such method has been 
suggested in the literature but it considers each PK measure individually (Panhardt 2007). 
Multivariate extensions are considered in this dissertation.  
In Chapter 2, a review of the literature on the topics of BE are presented. The 
chapter will discuss the methods of BE testing, types of BE tests, the PK used in testing 
for bioequivalence. Methods of estimating these PK are also presented and compared.  
Chapter 3 will present the development of a methodology to simultaneously 
evaluate population BE using multiple PK. A multivariate extension of the FDA 
approved PBE criterion will be derived. A method to implement the proposed 
multivariate criterion will be presented. Also in this chapter a method to simultaneously 
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estimate the PK parameters from a  nonlinear mixed effects models and test for BE using 
the proposed multivariate method will be presented.  
In Chapter 4 the design and results of a simulation study to evaluate the 
multivariate criterion in testing for PBE are presented. The size and power of testing BE 
using this criterion are evaluated. The definition of the acceptable BE regions and 
regulatory limits are discussed, especially with the introduction of the covariance as a 
new factor in defining these regions.  
In Chapters 5 and 6, the material from chapter 3 and 4 are consolidated in the 
form of two journal articles. The first paper (chapter 5) will introduce the multivariate 
extension to the PBE that accounts for the correlation between the pharmacokinetic 
variables. This paper will also include an illustration of the method using an existing data 
and a comparisons to other methods available in the literature. The second paper (Chapter 
6) will focus on the nonlinear methods. 
In Chapter 7, summary and conclusions of the finding of this research are 
presented along with the limitations and future work. Several appendices are 
supplementing this study. Appendix I provides mathematical presentation of PBE as a 
distance measure.  The SAS programs used for this dissertation and tables of the data 
used in the examples. Since the chapters are written in the form of journal manuscripts, 
the mathematical derivations of the PBE criterion are presented in Appendix II. The 
distribution histograms, and blood concentration profiles for all subjects in this study are 
also displayed in the appendices C, E and F. 
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2 Background 
2.1. Introduction  
Bioequivalence studies are used in the development of generic drugs and the 
development of new formulations of drugs that were previously approved. Developing a 
new drug and obtaining approval from the Food and Drug Administration (FDA) requires 
multiple clinical trials to document the toxicity and the efficacy of the pharmacologically 
active ingredients of the new drug. A generic formulation of an approved compound is 
not subject to the multiple clinical trial requirement of a new compound because it is 
assumed that the active ingredients of the generic drug have the same toxicity and 
therapeutic efficacy as the approved drug. Thus, a generic drug needs only to demonstrate 
bioequivalence to the approved drug; once bioequivalence is demonstrated, it is also 
assumed that the therapeutic efficacy is similar between the approved and generic drugs. 
Thus the bioequivalence studies are designed to establish this expected similarity of the 
generic drugs to the approved drug having the same active ingredients.  
Experiments are designed to measure the concentration of the active ingredient of 
both the test and the reference drugs in the blood, or in the biological site of action, at 
appropriate time intervals. A profile of the concentration of the drug over time is then 
generated. Several pharmacokinetic parameters are estimated from the concentration by 
time profiles and are used to quantify bioavailability. In general the PK parameters of 
interest are, the maximum absorbed drug ( AUC ), the time ( maxT ) at which the highest 
 25 
 
concentration in the blood ( maxC ) occurs, rates of absorption ( 0k and ka ), rate of 
elimination( ke ),  and blood or plasma half lives( 0.5t ) are calculated. 
2.2. BE a function of distance 
For any given metric two drugs are defined to be bioequivalent if  
 
2  , (4) 
where   is a predefined constant, and for any given metric,  is a critical value obtained 
from the distribution of a distance function of the new and the reference drugs. The upper 
limit ( ) is often prescribed by regulatory agencies. The  in general is the (1 - )th 
percentile of the distribution of the distance function for a given confidence level  .  For 
instance, if the 90% confidence interval of the distance function falls completely within 
the interval  ,  , bioequivalence is concluded. This procedure is equivalent to testing 
two one-sided hypotheses such as those mentioned in section 1.2 each at level  using an 
analogous test (Schuirmann, 1987).   
The ABE test focuses on the differences in the means of the pharmacokinetic 
parameters.  
   T R    , (5) 
The US FDA‘s guideline suggests comparing this distance measure with a BE 
predefined limit ( ) that is equal to 20% of the reference mean. BE is concluded when 
the confidence interval of the distance is within the BE acceptance region, i.e. 
 ˆ ˆ0.2 ,0.2R R  , where ˆR  is the estimated mean of the PK of the reference drug. The 
distribution of the PKs used in bioequivalence testing like maxC  and AUC  are known to 
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be lognormal, so the log-transformed parameters are often used in evaluating 
bioequivalence. The confidence interval of the distance measure   is estimated as 
     ˆ ˆ ˆ ˆˆ ˆ ˆ ˆ ˆ ˆ,
T R T RT R T R
z z                (6) 
 
where ˆ ˆT R  is the difference between the two estimated means of the PK parameter 
for drug T and R, and ˆ ˆˆ
T R 
  is the estimated standard deviation of the difference 
between the means.  
This method of evaluating bioequivalence, does not account for differences in the 
variability between the reference and test drugs. PBE was proposed to evaluate 
prescribability of the drug. Prescribability of a drug is defined as the ability to get the 
same effect by prescribing the brand-name drug or its generic drug to a new patient 
(Chow and Liu, 1992). In contrast to average BE, the PBE includes comparisons of the 
means and the total variability of the pharmacokinetic measures between the reference 
and test drugs (Hauk and Anderson, 1992).  
The PBE was introduced by FDA in 1997 as an alternative method of testing BE. 
The PBE is a scaled distance between the test and reference distributions with respect to 
the first two moments while the ABE is simply the difference between the first moments 
only. The PBE may be thought of as the ratio of two expected squared distances where 
the numerator is the expected squared distance between the reference and the test and the 
denominator is the expected squared distance between two reference observations. 
Bioequivalence, then is determined by the ratio of the two expected squared differences is 
within a predefined distance, , from unity. That is,  
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 
 
2
1
2
E y yT R
E y yR R

 
    
    
 (7) 
where yT  is a random variable denoting the test PK metrics, yR and yR are two 
realizations of the reference random variable and E represents the expectation.  
The univariate PBE criterion in (7), by substituting the unit ratio of the 
denominator term for the 1, could be redefined as (Sheiner 1992, Schall and Luus  1993), 
 
   
 
2 2
2
2
E y y E y yT R R R
E y yR R

             
    
. (8) 
Rewriting equation (8) in terms of the population mean and variance, it reduces to, 
 
 2 2 2
2
T R T RC
R
   


  
  . (9) 
where R and T are the means of the reference and the test random variables 
respectively, and 2
R
 and 2
T
 are the population variances of the reference and test 
pharmacokinetics respectively. Thus, the 
2 from the original inequality in (4)  is a 
function both of a distance metric of the means as well as the variances. The hypothesis 
test form of PBE uses the hypotheses 0 :  vs :aH C H C   . Bioequivalence is 
concluded with 100  1  % confidence if (1 )Cˆ    , where (1 )Cˆ  is the estimate of 
the upper limit of the one-sided 100(1 )th confidence interval of the PBE criterion 
defined in (9) using the maximum likelihood estimates (mle‘s) of the means and 
variances. 
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Extending this to more than one metric requires accommodation of the 
correlation. For example, suppose that the blood absorption coefficient ( aK ), and the 
time ( maxT ) until the maximum concentration ( maxC ) of the blood concentration is 
reached, and the area under the blood concentration curve ( AUC ), are all calculated from 
the same blood concentration-time profile. In this case, the assumption of independence 
in testing bioequivalence using multiple tests for each of the four parameters is not 
justifiable. Clearly, the correlations among these variables should be incorporated in the 
multivariate tests of bioequivalence. 
2.3. Multivariate extensions of BE assessment  
Multiple multivariate extensions for the average BE (Brown, 1995; Berger and 
Hsu, 1996; Brown, 1997; Munk and Pflujer, 1999; Wang, 1999; and Tamhane and 
Logan, 2004) have been proposed in the literature. However, there are only a couple that 
deal with the multivariate PBE. The first notable exception is  Dragalin et al. (2003), in 
which the Kullback–Leibler divergence (KLD) is used as a measure of discrepancy 
between the distributions of the two formulations. They propose a generalization of 
average and PBE measures, and generalize it to the multivariate situation. Their 
multivariate method could be summarized as follows. Consider a multivariate random 
variable Y  representing a set of PK metrics. Suppose Y  is distributed as normal with 
mean vector μ  and variance covariance matrixΣ . Let T and R represent test and 
reference treatments, respectively. The criterion proposed by Dragalin et al. (2003) is 
based on the following inequality 
    1 1 1 22 trace pT R T R T R T R                μ μ μ μ Σ Σ Σ Σ  (10) 
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Here, the left hand side (LHS) of the equation is the KLD. Two formulations are 
declared bioequivalent if the upper bound of a level-  confidence interval for the KLD 
is less than a given specific value,  . This criterion does not reduce to the univariate 
criterion proposed by the FDA in equation(9); instead it reduces to 
 
   2 22 2 2 21
2 22
T R T RT R R T
R T
       
 
      
 
 
  
 (11) 
Thus, this criterion may be seen as the average of two terms where the first term is the 
same measure of distance scaled by the reference variance proposed by FDA. The second 
term is similar except that it is scaled by the variance of the test. This criterion is 
equivalent to the FDA proposed criterion only if the reference and test variances are 
equal, in which case it is only a measure of the squared mean distances. Dragolin et al. 
argue that the measure proposed by the FDA is not a well defined distance measure, 
while the LHS of equation (10) is. However, the purpose of scaling the measure only 
with respect to the reference variance attributes more weight to the well established drug.  
The second notable exception is Chervoneva et al. (2007) who propose a criterion 
using the trace of the variance-covariance matrices. Although this criterion reduces to the 
univariate PBE when p, the number of variables, is one, it does not incorporate the 
correlations. The trace of a matrix being the sum of the diagonal elements alone ignores 
the off diagonal elements which represent the covariances.   
The bioequivalence rule proposed by Chervenova et. al. (2007) is, 
 
       
 
tr trT R T R T R
Bp
tr R

   
 
μ μ μ μ Σ Σ
Σ
 . (12) 
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They linearize this inequality by writing,  
          tr tr trT R T R T R R    μ μ μ μ Σ Σ Σ , (13) 
which reduces to, 
          1 0tr trT R T R T R     μ μ μ μ Σ Σ . (14) 
They then construct estimates of the confidence interval for the LHS of the above 
inequality by developing confidence intervals of the traces and the quadratic term. They 
calculate the predefined  using the same limits of differences in means and variances 
defined by the FDA in the univariate case. They concluded BE when the upper limit of 
the 90% confidence interval is negative. For p = 1 this rule reduces to the univariate rule 
in equation (9) .  
In chapter 4 the implementation of the criterion suggested in equation (8) will be 
discussed and the two measures presented here will be compared to the criterion 
proposed in the chapter 3. One of the main issues in the two methods presented here and 
the one that is proposed in chapter 3 is regarding the specification of the upper limit, . 
Next, this is discussed briefly. 
2.4. Upper bounds of PBE defined by FDA 
 In the univariate case,   is defined according to predetermined limits determined 
by the FDA. The maximum difference between the variances of the test and the reference 
( 2 2
T R
  ) allowed by FDA (1997) is 0.02, and the minimum allowed variance of the 
reference ( 2
R
 ) is 0.04. This minimum variance was motivated by the population 
difference ratio (PDR) and the corresponding criterion for ABE. The PDR is defined as 
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the square root of the ratio of the expected squared difference of the pharmacokinetic 
measure of the test and the reference to the expected squared difference of the same 
under replicated administration of the reference drug. The FDA defined 1.25 as the 
maximum allowable value of PDR to consider the two drugs bioequivalent. Notice that 
PDR will reduce to a function of the PBE criterion C in equation(9). That is, 
1
2
C
PDR   . The FDA also sets the upper limit of  T R  to the natural log of 1.25 
to accept bioequivalence according to the ‗80/125‘ rule, where the ratio between the test 
and reference means should lie within the [80%, 125%] range. Using these facts and 
assuming that 2 2
T R
  , the minimum value of 2
R
  that fulfills FDA‘s maximum 
allowable value of PDR is about 0.04, and the maximum value of   that determines PBE 
is 1.75 (Appendix C). 
The FDA proposed the limits for the PBE upper bounds for the univariate case only. 
No guidance was provided for the multivariate case.  Chervenova et al. (2007), used the 
same limits for each of the variables in the multivariate method they suggested. Their 
method ignored the correlations between the variable. The correlations should be 
accounted for and their effects need to be studied.  This important issue will be further 
considered in chapters 3 and 4.   
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3 A multivariate criterion for testing PBE 
In the previous chapter two multivariate criteria for testing BE were discussed. It was 
noted that these criteria are not appropriate analogs of the univariate FDA approved 
criterion. In this chapter, a multivariate criterion that is based on the motivation of the 
univariate FDA criterion is derived, and a method to implement it is presented. 
3.1. Development of the multivariate bioequivalence criterion C p  
The univariate PBE criterion is expressed as  
 
   
 
2 2
2
2
E Y Y E Y YT R R R
E Y YR R
            
    
. (15) 
To develop the multivariate equivalent for the criterion in (15), let TY and RY be p-
variate random variables denoting the test and reference PK metrics. Assume, TY is 
distributed as a p-variate normal with a mean Tμ  and a variance covariance matrix TΣ  
and let RY  and RY be two realizations of the p-variate normally distributed random 
variables with mean vector Rμ  and a variance covariance matrix RΣ . 
Then the multivariate equivalent of the denominator in(15) is   
   
1
2
E R R R R R
      
Y Y Y Y Σ . (16) 
Then the multivariate criterion that is equivalent to (9) could be written, 
        1 1C E Ep T R R T R R R R R R
                 
Y Y Σ Y Y Y Y Σ Y Y  (17) 
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To prove this, let  1 2R T R
 Z Σ Y Y  and let  1 2R R R

 K Σ Y Y , then by 
substituting Z  and K  appropriately in (17), the multivariate criterion could be expressed 
as  
    C E Ep   Z Z K K  (18) 
Note that  
 
 
 
 
 
     
2 2 ,
1 1
22 ,
1
22 ,
1
22 ,
1 1
.
p p
E E z E zi i
i i
p
E zizi
i
p
E zizi
i
p p
E zizi
i i
trace E E



 
    
   
  
 
  
 

 
  
 

 
 
 
 


 
Z Z
Σ Z ZZ
 (19) 
Similarly,        E trace E E  KK Σ K KK . Substituting these in (19),  the 
multivariate PBE criterion reduces to, 
            C trace E E trace E Ep     Σ Z Z Σ K KZ K . (20) 
The expected value of Z is 
 
   
 
 
1 2 ,
1 2 ,
1 2 .
E E R T R
ER T R
R T R
  
  
    
 
Z Σ Y Y
Σ Y Y
Σ μ μ
 (21) 
Therefore the second term of the right hand side of (20) is  
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       
   
1 2 1 2 ,
1 .
E E T R R R T R
T R R T R
    
  
Z Z μ μ Σ Σ μ μ
μ μ Σ μ μ
 (22) 
The expected value of K  is,  
 
   
 
 
1 2 ,
1 2 ,
1 2 ,
.
E E R R R
ER R R
R R R
     
     
 

K Σ Y Y
Σ Y Y
Σ μ μ
0
 (23) 
Note that the variance covariance matrix of Z is:  
 
 
  
 
    
 
,
1 2 ,
1 2 1 2,
1 2 1 2,
1 2 1 2,
1 2 1 2 1 2 1 2.
V
V R T R
CovR T R R
Cov CovR T R R
R T R R
R T R R R R

 
  
  
  
    
Σ ZZ
Σ Y Y
Σ Y Y Σ
Σ Y Y Σ
Σ Σ Σ Σ
Σ Σ Σ Σ Σ Σ
 (24) 
The last term of the above equation reduces to a p x p identity matrix, I, and thus the 
variance-covariance matrix of Z  reduces to 1 2 1 2R T R
  Σ Σ Σ I .                                             
Similarly the variance covariance matrix of K  
 
 
  
    
 
,
1 2 ,
1 2 1 2,
1 2 1 2,
2 .
V KK
V R R R
Cov CovR R R R
R R R R

  
   
  

Σ
Σ Y Y
Σ Y Y Σ
Σ Σ Σ Σ
I
 (25) 
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Substituting these into (20) and using the cyclical properties of the trace, the multivariate 
criterion could be expressed as 
           
       
     
,
1 2 1 2 1 2 ,
1 1 .
C trace E E trace E Ep Z K
trace traceR T R T R R T R
trace pT R T R R T R
    
       
     
Σ Z Z Σ K K
Σ Σ Σ I μ μ Σ μ μ I
Σ Σ μ μ Σ μ μ
 
It is simple to show that this multivariate criterion reduces to the univariate 
criterion (9) when p = 1. It also accounts for the total variability and the correlations 
among the PK metrics used in evaluating bioequivalence. 
Using the invariance property, the maximum likelihood estimator (mle) of the 
multivariate PBE criterion could be obtained from the data as: 
      1 1ˆ ˆ ˆ ˆˆ ˆ ˆ ˆC trace pp T R T R R T R     Σ Σ μ μ Σ μ μ , (26) 
where ˆTμ  and ˆ Rμ are the mle‘s of the population means, and 
ˆ
TΣ  and 
ˆ
RΣ are the mle‘s 
of the variance covariance matrices of the test and reference variables.  
 
3.2. Hypothesis Testing of Multivariate PBE 
Using the proposed multivariate criterion ( C p ), the hypotheses for multivariate PBE are 
 0 :  vs :p a pH C H C   , (27) 
where C p is the p-variable PBE criterion and  is the constant predetermined by the 
regulators as the upper acceptable value for the acceptance region. One could define the 
test statistic based on the mle of the C p . However, the exact distribution of the test 
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statistic is not tractable. Therefore, numerical methods such as the Bootstrap algorithm 
have to be used to determine the distribution. In general, a size  test could be defined 
as,  
 
 
ˆ1 if 1 ,
( , )
ˆ0 if 1 .
p
R T
p
C
y y
C
 

 
  
 
 
,  (28) 
 
where
R
y  and 
T
y  are the sample observations, and  ˆ 1pC  is the (1 )100th percentile 
of the distribution of the mle of the PBE criterion. This test rejects the null hypothesis of 
no BE when the test statistic is 1.  Equivalently, the multivariate bioequivalence will be 
concluded at significance level   if the upper bound of the confidence interval for pC , 
namely  ˆ 1pC  is less than .  
3.2.1. Constructing the100(1 )th confidence interval of pC  
The exact distribution of the MV criterion of the mle Cˆp is not tractable. 
Therefore, a parametric bootstrap method (Efron & Tibshirani, 1993), as recommended 
by the FDA, is proposed. The steps of the parametric bootstrap method are: 
1. Obtain the mle‘s of the population parameters Tμ and TΣ of the test and Rμ and 
RΣ of the reference metrics. Calculate the MV PBE criterion using (26).  
2. Generate B pairs of bootstrap random samples. Each pair is made up of two 
random samples of size nT (the number test drug samples) and nR  (the number 
of reference drug samples), selected from a multivariate normal distribution with 
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mean vector ˆT  and covariance matrix 
ˆ
T for the test drug; and mean vector 
ˆR  and covariance matrix 
ˆ
R for the reference drug.  
3. For each pair of the b-th sample calculate the mle‘s of the means, ˆTb  and 
ˆRb and the mle‘s of the variance covariance matrices,
ˆ
Tb and 
ˆ
Rb , for b   
1,...,B . Calculate the bootstrap estimate of the MV population criterion Cˆpb for 
each bootstrap sample. 
4. Determine,  ˆ 1Cpb  , the 100(1 )th percentile of the distribution of 
C pb based on the B bootstrap samples. 
5. PBE will be concluded if  ˆ 1Cpb    . 
3.3. Specifying the upper limit, , of BE 
 In Chapter 2, the limits and rational of BE acceptance used in calculating the 
univariate   determined by the FDA were presented. These limits are extended to the 
multivariate criterion, by setting the maximum difference between the means of the test 
and reference pharmacokinetic measures as the natural logarithm of 1.25; the maximum 
difference between the test and reference variances as 0.02, and the lowest variances as 
0.04. Since there is no analogous guideline for incorporating the correlations, different 
combinations of correlations among the test and reference variables will be used. In the 
case of independence of the two measures (i.e., 0T   
and 0R  ),   reduces to p-
multiples of the univariate  , where p is the number of variables. That is, 
1.75p pp   , leading to a rectangular region of BE rather than an elliptical region. 
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Using the proposed multivariable limits, values of   could be calculated for the case 
where  p = 2 with the BE limits of means and variance differences as defined by FDA. To 
account for the correlations, since there are no FDA specifications, the   could be 
computed for a range of values of R  and T .   
 Figure 2 shows the change in   in the positive range of the correlations. It is 
unlikely to find negative correlations between the AUC  and maxC . The horizontal 
reference line in the graph crosses the y-axis at 3.49 which is the value of   when the 
reference variables are independent (i.e., 0R  ). This value is noted as 0 . Also, when 
the reference variables are independent, (i.e., 0R  ), the value of   is a constant 
(equal to 3.49) regardless of the correlation between the test variables.  
The plot also illustrates, the value of   is always lower than 0 when the correlation 
between the reference variables is less than or equal to 0.4. For reference correlations 
greater than 0.4, the value of   is smaller than or greater than 0  depending on the 
values of R  and T . Since C p  is scaled by the reference variance covariance matrix,  
is more sensitive as the difference between the reference correlation and the test 
correlations increase. The (second) figure shows the plot of versus correlation when the 
two correlations are assumed equal. Notice that in the positive range of values the plot is 
close to the horizontal line representing independence.  However, the plot is consistently 
below the horizontal line. That is, the value of    is always smaller than 0 , calculated 
ignoring the correlation. As expected, this suggests, the acceptance region of BE will be 
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smaller when accounting for the correlations.  (Most of the PK variables are generally 
positively correlated.) 
In summary, these plots show, accounting for the correlations is necessary if the 
correlation between the variables in the reference and the test are expected to be vastly 
different. Further, when the correlations are vastly different guidance from the regulatory 
bodies is needed to determine the right upper bound. In the meanwhile, the BE should be 
tested for the most conservative bound. This problem becomes more complicated for p 
greater than two. Table 1 lists the values of   for the case where the correlations in the 
reference and the test are assumed equal, in the case of p=3. In this case there are three 
correlations, the first between the first and second PK, the second between the first and 
third PK, and the third correlation between the second and third PK. the value    when 
all the correlations are equal decreases as the correlation increases. When fixing the 
correlations between any two PK at low or medium values the value of   decreases by 
increasing the third correlation. This pattern is not the same when fixing two correlations 
at high value (like 0.8), the value of  increases from 2.39 when the third correlation is 
zero to 7.72 when the third correlations is at medium value, but   drops to 2.94 when the 
correlation is high at 0.8. The table also demonstrates that the values of   are higher in 
the case of p=3 than they are in the case of p=2. 
Table 1 comparison of  by different correlations among PK when p=3 
12  13

 23

 
  
0 0 0 5.23 
0 0 0.3 4.66 
0 0 0.8 4.13 
0 0.3 0.3 4.23 
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0 0.3 0.8 4.04 
0 0.8 0.8 2.39 
0.3 0.3 0.3 3.83 
0.3 0.3 0.8 3.50 
0.3 0.8 0.8 7.72 
0.8 0.8 0.8 2.94 
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Figure 2: Effect of R  and T on the rule   
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Figure 3  with the BE limits of mu and var differences, and equal R  and T  
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3.4. Determination of PK parameters using model based estimation 
It is known in PK that the drugs and other chemicals are absorbed, metabolized, 
and eliminated from the body according to mechanisms that are specific to each drug or 
groups of drugs and their physio-chemical metabolic pathways, in the anatomical 
compartments they are distributed through. These mechanisms could be represented 
mathematically through differential equations from which non-linear functional forms of 
blood/serum concentration profiles could be derived. In the area of pharmaco-kinetics 
these are known as one, two or higher order compartmental models. These models 
assume the existence of multiple separate but connected compartments in the body where 
the drug will be absorbed and eliminated from. In each compartment the constants of 
absorption and elimination are unique for that compartment. The absorption of each drug 
could be assessed using non-compartmental methods like zero-order models as discussed 
in chapter 1. As mentioned in chapter 1, the AUC resultant from a single dose of a drug 
formulation is commonly assessed with the linear trapezoidal method (Berger RL, 1996, 
Gibaldi, 1982), ignoring the mechanistic non-linear nature of the concentration profile. 
This is mainly because in the early phases of drug development these models might not 
be known. The non-linear functional form of the PK mechanisms of approved drugs are 
always studied extensively during and after the approval of the drug. However, after the 
approval of the drug, and before the development of new formulations or generic drugs 
the characteristics of the non-linear function would be studied from which they could be 
well specified and all the characteristics of the plasma-concentration curves could be 
determined.  Acquiring this knowledge and the availability of advance analytic software 
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makes it logical to use compartmental or model-based methods for estimating the metrics 
used in evaluating bioequivalence. 
Non-linear models have been used in pharmacology to study the PKs of drugs for 
a long time. These models could be based on theoretical models describing the 
underlying mechanism that produces the data. As a consequence, the non-linear model 
parameters have a better physical interpretation (Adams, 2002). However, these models 
are not generally used in drug testing, except for very limited tasks, like estimating the 
constants of absorption and elimination. Even in situations where non-linear models are 
used to estimate the other PK metrics such as AUC and maxC only point estimates are 
used in the bioequivalence testing. The uncertainties in the estimation are ignored (FDA 
1992-2001, Chow SC, Liu JP 2000).    
 
3.5. Analysis of pharmacological functions using nonlinear models  
 
Consider the one-compartment pharmacological model that determines the drug 
concentration in the plasma or blood at any time point according to this function: 
 
 
k t k ta e e a
a e
k k D
C e e
Cl k k
   
 
, (29) 
where C is the plasma concentration, D  is the dose, Cl  is the clearance, t is the time of 
the measurement, ka is the constant of absorption, and ke is the constant of elimination. 
Note that the clearance rate of the drug is eCl k V , where V is the volume of the active 
compartment. The area under the curve AUC , could be estimated by integrating the 
plasma concentration with respect to time of the concentration function in (29). That is,
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 
0
k t k ta e e a
a e
k k D
AUC Cdt e e dt
Cl k k

    
  
,  (30) 
which yields 
D
AUC
Cl
 . If one is interested in AUC alone, the function could be re-
parameterized in terms of AUC by substituting AUC  for the ratio of the dose ( D ) to the 
clearance ( Cl ). That is, the model could be rewritten 
 
 
* k t k ta e e a
a e
AUC k k
C e e
k k
   
 
.     (31) 
Similarly maxC could be calculated by differentiating  (29) with respect to t and equating 
it to zero. This yields the equation, 
 
 
0
k t k ta e e a
a e
k k DC
e e
t Cl k k
 
          
 (32) 
Solving the above equation yields, 
 
max max
max
k T k Ta e e a
a e
k k D
C e e
Cl k k
   
 
, where 
maxT is calculated as 
   
 
ln lne a
e a
k k
k k


. Other PK parameters such as the first order rate of 
absorption ak , and the rate of drug elimination, ek , could also be determined from these 
models through appropriate mathematical manipulations.  
3.6. Modeling BE experiments using Nonlinear mixed effects models  
Consider a bioequivalence study comparing a new test drug to a reference drug. In 
such studies, which are usually designed as cross-over studies, each subject receives both 
treatments, and he/she might receive each treatment multiple times. So these correlated 
repeated measures need to be accounted for when estimating the fixed effects.  Suppose, 
the blood-concentration by time profile of the reference drug could be represented by a 
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known non-linear function f linking concentrations to sampling times of all the subjects 
with subject specific PK parameters, such as absorption ( ka ), elimination ( ke )rate 
constants, and clearance half-life ( Cl ). An example of this function is the one 
compartment model function in (29) 
Suppose several subjects are observed over a time interval at different occasions 
(of periods) on different treatments.  At time point, tijpk , let Cijpk  represent the blood-
concentration  of the 
thk  treatment given to the 
thi  subject at the thj time point, in the 
thp  period. Here  i  = 1, 2, …, n, k = T or R,  p= 1, 2, …, P, and j  = 1, 2, …, tipk , for, 
n subjects, 2 treatments, P periods and tipk  time points. Assume that the sampling times 
are fixed and identical, for each treatment, period, and for all subjects, as often is the case 
in cross-over trials. Then for all , , ,i j p and k , the time tijpk  could be simplified to t j . 
Let ipkλ be the vector of the PK parameters of the subject i for treatment k in period p. 
Then the nonlinear model for the concentration profile is, 
  ,C f tijpk j ipk ijpk λ , (33) 
where ijpk is the measurement error. It is also assumed that ijpk  are independent of 
ipkλ , and they are normally distributed with mean zero and variance 
2
ijpk
 . 
Assume that the parameters ipkλ   are random vectors that could be decomposed for each 
period and treatment as 
 .ipk k p ik   λ μ β γ u  (34) 
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where .μ is the overall mean, kβ is the fixed effect of the treatment, pγ is the fixed effect 
of the period, and iku is the random effect of subject i for treatment k , it is also assumed 
that iku is distributed as a multivariate normal with mean zero vector and a variance 
covariance matrix  kΨ . 
To ensure that the estimates are always positive, ipkλ  elements are the natural 
logarithms of the original PK parameters in the function f. The elements of ipkλ  are  
     log , log ,  logipk a eipk ipkCl k k    . 
The mle‘s of the original PK parameters: ka  , ke , and Cl  could be estimated 
using this nonlinear mixed effects model. Since maxC and AUC  or other metrics are 
functions of these PK parameters, then the mle‘s of these metrics for each treatment 
group could be estimated as functions of the mle‘s of the PK. The asymptotic 
approximation of the variance covariance matrices of these metrics could be estimated 
using the Taylor series expansion theorem. Where the second partial  derivatives are 
derived and the mles are estimated. This method is known as the delta method. When  
closed form derivatives are available, the estimation of the information matrix is easy. 
Otherwise other methods are utilized. 
Using these estimates of the means and variance covariance matrices of the test 
and the reference drugs, the multivariate PBE criterion ( C p  ) that was proposed in 
section 3.1 is estimated. Then the 90% confidence interval is constructed around this 
estimate using the parametric bootstrap method as suggested by the FDA and as shown in 
our first paper. Two thousand samples are randomly generated from a multivariate 
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distribution with means and variances equal to the mle‘s obtained from the NLMEM. The 
upper limit of the resultant confidence interval is compared to the predefined limit of 
bioequivalence   described earlier in the chapter. Bioequivalence is concluded if the 
upper limit of the 90% confidence interval is smaller than the predefined limit  . 
3.6.1 Modeling cross-over experimental design 
The cross-over design is the most recommended design for bioequivalence 
studies. In this design subjects are randomized to receive one of the sequences of 
treatments. Each of these sequences contains both the test and the reference drugs at 
different periods. For example in the two period cross-over design, one sequence is TR, 
and the other treatment is RT. A washout period should follow any treatment period to 
make sure no effect of the drug from the previous period will affect the consecutive 
period. In multiple period designs, the order in which the two drugs are given is usually 
selected at random using a block randomization method to ensure the balance within 
subjects. 
 At the beginning of each period, baseline blood concentration data are collected 
prior to the administration of the drug to evaluate the washout period. The 
pharmacological baseline measurement is supposed to be zero if the wash out period is 
long enough. After the drug is administered, the specified pharmacological measurement 
(level of specific active material in the blood) is obtained over a period of time at fixed 
time intervals predesigned according to the investigators knowledge and expectations 
about the pharmacodynamics of the tested drug. 
In this design, each subject receives both treatments, and one or more administrations of 
each treatment according the sequence assigned to him/her. Under this design, all 
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measures within each subject are correlated. The goal was to determine if the two drugs 
are bioequivalent. The NLMEM presented above in equation (34) is a suitable model for 
this design because the administrations are repeated in nature on each subject, and due to 
the expected missing data in such experiments. Using the same notation above the 
parameter vector could be decomposed as (34). 
 
3.6.2 Modeling parallel experimental design 
 
Although parallel designs are not the recommended designs for testing BE, in 
practice some drugs cannot be tested using other designs. In this design patients are 
randomized to either receive the test or the reference treatment. Similar to the nonlinear 
mixed effects model (NLMEM) described above. A fixed effect model could be 
constructed by excluding the period effect, and the random effect of the subject. This 
could be used to model the one-compartment pharmacological model that fits such data.  
Using the same notations above, the vector ikλ  is a fixed effects vector that can be 
decomposition as 
 .k k λ μ β  (35) 
where .μ is the mean value of all treatments, β is the coefficient of the fixed effect 
According to this model, the vector kλ , could be defined as      log , log ,  loga eCl k k    
 . 1 2 3, ,  μ , and  1 2 3, ,k k k k  β . The pharmacological function in (29) could 
be fit in the nonlinear model by substituting the PK parameters Cl  , ak , and ek  by the 
exponentials of the members of the fixed effect vector ikλ ; i.e.  1 1k  ,  2 2k  , 
and  3 3k   respectively.
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3.7. Summary of the method 
The estimates of the PK parameters for each treatment and the variance 
covariance matrices could be estimated as in section 3.6. The MV criterion would be 
estimated and the upper limit of the confidence interval, constructed using the bootstrap 
method, would be compared to the predefined limit   to evaluate PBE.
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4 Simulation Study 
 
 
In this chapter, properties of the multivariate PBE criterion proposed in the 
previous chapter are studied using Monte-Carlo simulation methods. The simulation 
study was designed to evaluate the distribution of the proposed multivariate criterion C p  
under different combinations of sample size (number of subjects in the trial), differences 
in the averages and variances of the pharmacokinetic (PK) parameters between the 
reference and test drugs, and under different correlations among the PK parameters 
within each treatment group. This study was mainly designed to guide in the selection of 
a method to construct the confidence interval for the proposed criterion. Another 
simulation study was designed to study the size and power of the hypothesis tests, and to 
compare the multivariate criterion versus the multiple testing using the univariate criteria. 
These studies were limited to equal size samples of reference and test drugs. The effect of 
different sample sizes, missing values and dependence between the treatments drugs 
should be examined in future studies. 
4.1. Generating p-variate normally distributed data 
 It has been shown in many studies that the log-transformed pharmacokinetic 
parameters have a normal distribution, and that data extracted from the same 
concentration time profiles for each subject are correlated. To create samples that 
preserve these properties samples for the simulations were drawn from multivariate 
normal distribution. Two samplesYT and Y R  of N sets of pairs of variables were 
generated from a bivariate normal distribution to represent the test and reference datasets.  
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The first dataset includes variable 
1
y
R i
 and 
2
y
R i
hat represent the log-transformed 
pharmacokinetic parameters of the reference drug, namely log( )maxC and log( )AUC . 
The second dataset includes 
1
y
T i
and 
2
y
T i
that represent the log-transformed data of the 
test drug, where i  represents the 
thi subject, for 1,...,i N . The corresponding data 
matrices are  
.  .  .
11 12 1
,
.  .  .
21 22 2
.  .  .
11 12 1
.
.  .  .
21 22 2
y y y
T T T N
T
y y y
T T T N
y y y
R R R N
R
y y y
R R R N
 
  
  
 
  
  
Y
Y
 
have samples of bivariate normal distributions, which we will denote by 
~ ( , ),N pk k k
Y μ Σ  
where the subscript k represent the treatment, T, Rk  . For treatment k the population 
mean vector is 
 , ,1 2k kk  μ  
and the variance covariance matrix is 
2
1 1 2
.
2
1 2 2
k k kk
k
k k k k
 
 
 
  
Σ
   
   
 
In the case of more than two PK, this covariance structure allows for different 
correlations between the pharmacokinetic variables within each of the two drugs. For the 
simulation a parallel design is assumed, so that the observations from the two treatments 
are assumed independent. This assumption is widely accepted in the case of the 
univariate evaluation of PBE.  
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 SAS IML code calling the function (VNORMAL) was used in a macro to 
generate the samples of bivariate normal data. All simulations and analyses were done 
using SAS 9.2, SAS Institute, Cary, NC. Code is presented in Appendix K.   
 
4.1.1  Evaluation of the distribution of the multivariate BE criterion. 
 A preliminary Monte-Carlo experiment was performed to study the distributions 
of the multivariate criterion. The results in Appendix C show that the distributions are 
skewed to the right, especially in smaller sample sizes. As the sample size increases the 
distribution gets closer to a symmetric normal distribution. The distribution under equal 
correlations, and three sample sizes (25, 50, and 100), were examined. Distribution 
histograms in Appendix C show that with a small sample size (n = 25) the distribution of 
the estimate of PBE criterion, C p , is far from normality. As the sample size increases, 
the distribution approaches normality. However, if the distribution was investigated by 
the difference between the covariances of reference and the test, then this study 
demonstrates that these difference specific distributions  are far from the normal 
distribution even with the larger sample sizes (n = 100). 
 The results of this Monte-Carlo experiment (presented in Appendix C) supported 
FDA‘s recommendation of using the bootstrap method to construct the confidence 
interval for the univariate PBE criterion rather than applying a normal approximation. It 
could be concluded that similar to the univariate case, using the parametric confidence 
intervals which assume normality for the multivariate PBE criterion C p  would not be 
appropriate. In order not to assume any distribution the parametric bootstrap method to 
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evaluate the percentile confidence interval was used as suggested by the FDA. The 
parametric bootstrap method was used because there is enough evidence that the log-
transformed pharmacokinetic measures like AUC, maxC and maxT  follow a normal 
distribution. It was convenient to resample (for the bootstrap) from a p-variate normal 
distribution in which means and variance covariance matrix are equal to those estimated 
from the sample.  
 
4.2. Constructing confidence intervals for the PBE Criterion C p  
 The non-parametric confidence interval was constructed using the percentiles 
from the parametric bootstrap method. From each replication of the experimental 
settings, the means and the variance covariance matrices were estimated. Then 2000 
bootstrap samples were generated by randomly selecting from multivariate normal 
distribution with mean and variance equal to those estimated from the replication. Then 
estimates of the multivariate PBE criterion C p were calculated for each of these 2000 
bootstrap samples. The 95
th
 bootstrap percentile of C p was determined. This is the upper 
limit of the one sided 95% confidence interval for C p that would be used in the 
hypothesis testing.  
 
4.3. Simulation Configurations 
The simulation study was run with 500 replicates. Each replicate represented a 
bioequivalence trial with N subjects in each treatment (test or reference). For each subject 
two measures representing the log-transformed AUC and maxC , were selected from the 
bivariate normal distribution as described earlier. To estimate the nonparametric 
 55 
 
confidence interval in each simulation, 2000 bootstrap samples were randomly selected 
from the bivariate distributions. Efron (1982) demonstrated that in general 2000 bootstrap 
samples would be large enough to obtain unbiased confidence intervals. 
 Following FDA guidelines for the univariate case of PBE, and based on the 
information from published bioequivalence trials the following factors and their levels 
were considered: 
1. Sample size (The number of subjects in each sample (N)): It is important to 
evaluate the performance of any new statistic or test under a variety of sample 
sizes. The usual number of subjects in most of the bioequivalence drug trials 
varies between 20 and 100 per group. So it was decided to choose the values 25, 
50 and 100. 
2. Difference in the means: As discussed earlier the maximum allowable difference 
between the (log transformed) means of the test and the reference parameters is 
the natural logarithm of 1.25. Five values for the difference between the means 
were selected: -2log(1.25),  -log(1.25)/2, zero, log(1.25), 2log(1.25). 
3. The standard deviations: The FDA recommends a minimum value for the 
reference standard deviation of 0.2, so it selected as the value for the variance of 
the reference pharmacokinetics. Hence, 2 2&
1 2R R
  were set to be 0.04.  
4. Difference in the variance: The FDA defines bioequivalence if the difference 
between the variances of the reference and the test pharmacokinetic is within 
0.02. We selected the values for the variance of the test PK to be 0.04, 0.06 and 
0.1. 
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5. Correlation between the pharmacokinetic variables: The correlations for variables 
are not used in the definition of bioequivalence. The correlations are ignored in 
the multiple univariate testing and in the MV criterion suggested by Chervoneva 
(2007). To evaluate the performance of the proposed criterion, a wide range of 
correlations that allow for all possible values including rare cases like negative 
correlations were selected. The correlations between -0.2 and 0.8 in increments of 
0.2 were selected to evaluate the effect of the difference between the correlations 
on the power and the size of the tests for bioequivalence.  
  The size of testing the hypotheses of BE was evaluated under conditions that 
represent the maximum allowable values of variances and differences between the 
means of the reference and test drugs. The power of the test was evaluated under 
conditions that fulfill the BE with respect to the variances and the means. The size 
and power were evaluated under different sample sizes and variable correlations 
between the reference and between the test variables.  
 
4.4. Description of the simulation steps 
In summary, the simulations was performed using the following steps for each of the 
combinations of sample size, difference in means, difference in variance and correlations 
between the reference and the correlations between the test PK measures: 
1. Generate 500 samples (replicates) of four random variables of size N from two  
bivariate normal distribution with reference means 1R  and 2R  and test means 
1T and 2T , and correlations R and T  and variances 
2
1R
 , 2
2R
 , 2
1T
 , and 
2
2T
 that define each configuration or setting. 
 57 
 
2. Estimate the means vector and variances covariance matrix for each replication. 
3. Bootstrap each replicate 2000 times using parametric bootstrap method by 
selecting 2000 random samples from multivariate normal distribution with the 
means and variances equal to those estimated in step 2. Calculate the estimated 
MV criterion Cˆpb for each bootstrap sample. The subscript b denotes bootstrap. 
4. Calculate the 95th percentile for the 2000 calculated bootstrap estimates of Cˆpb  
for each simulation configuration. Let this percentile be denoted ˆ (.95)Cp which is 
the upper limit of the one-side confidence interval of C p . 
5. For each replication, reject the null hypothesis if the upper bound of the one-sided 
95% confidence interval, ˆ (.95)Cp , was less than the predefined  . Calculate the 
number and percent of times the result was correct in agreement with the setting, 
and do the same using the univariate criterions for each of the variables. 
6. Calculate the size and power of the test by calculating the percentage of times the 
null hypothesis was rejected among the 500 replicates, if the null hypothesis was 
true or was not true respectively. 
 
4.5. Simulation Results 
 
The results of the simulation study are tabulated by sample size, the difference 
between the averages of each of the variables and the difference in the variances, the 
correlations of the reference and the correlations of the test drugs in the Appendices C 
and D. The results show that the size of the test is affected by the sample size, and the 
correlations. 
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4.5.1 Evaluation of size of the test 
The size of the test could be evaluated as the highest probability of rejecting the null 
hypothesis given the null hypothesis is true.  That is, using the definition 
   sup ( , ) 1Ho R TP y y   . (36) 
 In the example of bioequivalence this is the highest probability of determining two drugs 
as BE when they are actually not BE. 
 
The size of the test was evaluated using random selection from distributions that have the 
maximum accepted values of the differences between the means and between the 
variances. These values define the boundaries of the multivariate PBE acceptance region 
in all dimensions. These are the values that define the true value of the multivariate PBE 
criterion as equal to the predefined . The table compares between two tests, the first 
accounts for the correlation in the predefined , the second one ignores the correlations 
when defining  . The probability of type I error is very conservative in the case of 
smallest tested sample sizes of 25 and it increases by increasing the sample size. These 
errors exceed the 0.05 level only when the reference correlations are higher than 0.2, and 
the   is calculated under the assumption of independence. The largest probability of type 
I errors are observed when the correlations of either the reference or the test are very high 
(0.8), and when the differences between the correlations of the reference and the 
correlations among the test are large. 
Probability of the type I errors are also sensitive to the magnitude of the 
correlation used in calculating the   (Table 3). Testing the bioequivalence hypothesis 
using negative correlations, on samples drawn from positively correlated random 
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variables, causes the highest increase in type I errors. There is a minimal increase in 
probability of Type I error when using a positive correlation that is not equal to the true 
correlation except for testing with lower correlations when the true correlation is high 
0.8. This would result in rejecting the null hypothesis, and concluding PBE in more non-
BE cases.  
 
4.5.2 Evaluation of power of accepting BE 
Table 4 compares the power of the proposed multivariate PBE test as a function 
of the sample size, the correlations and the differences in the means and the difference 
between the variances. As expected the power is highest when there is no difference in 
the true means of the reference and test variables. The power drops gradually as the 
difference between the means increases in either direction. Accounting for the correlation 
in the upper limit, , of PBE results in a test with less power than ignoring the 
correlation. The power increases as the absolute difference between the test and reference 
means increases. The test that ignores the correlation achieves the highest power, while 
the intersection of two separate univariate tests has the lowest power. Data in Table 5 
presents the power as a function of the difference in the variances of the reference and 
test variables. The power increases as the sample size increases and as the difference 
between the variances decreases.  
Each simulation sample was classified as bioequivalent or not according to the 
proposed multivariate PBE test accounting for correlations, ignoring the correlations, and 
using the intersection of two univariate tests of BE with and without Bonferoni 
correction. Then according to each scenario the simulation samples were classified into 
correctly classified and incorrectly classified. Table 6 compares the correct classification 
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of all BE and non-BE scenarios using the four methods. The sensitivity of testing for BE 
is higher when ignoring the correlation than all other tests. This means that more 
scenarios are classifying correctly as BE when the truth is BE. However this higher 
sensitivity is at the cost of having the highest false positive rate or the lowest specificity, 
i.e. the highest proportion of misclassification (type I error or incorrect classification) 
when the truth is not BE.  
The power function was evaluated as a function of the test means under fixed 
values of the reference means and variance covariance matrix and under equal 
correlations between the test variables and between the reference variables. The x-axis in 
Figure 4 presents the value of the means of the test variables, assuming equal means for 
both PK. The acceptance region of Bioequivalence under these conditions is the area 
bounded by the two vertical lines in the graph which represent differences of (log 1.25) 
from the reference means. The figure shows that the power of rejecting the null 
hypothesis of ―no BE‖ is higher than 90% when the reference means are equal to the test 
means. This power decreases as the difference between the means increases. After 
crossing the acceptance boundaries, the vertical reference lines in the plot, the probability 
of rejecting ‗not BE‘ drops to below 0.05. The figure shows that this trend is common 
among all three test: i) comparing the multivariate criterion to a rule   that does not 
account for the correlation, ii) comparing the multivariate criterion to a rule   that does 
account for the correlation , iii) the intersection of two univariate comparisons of the 
univariate criterion to a univariate rule  .    
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Figure 5 presents the drop in the power of testing the null hypothesis of ‗no BE‘, 
under fixed variance of the reference, as the variance of the test increases. This power, as 
expected, increases as the sample size increases. The power is above 0.7 with sample size 
of 100 when the variance is 0.06, which is equivalent to a difference of  0.02 between the 
variances. As the variance of the test variable increases the probability of rejecting the 
null hypothesis of no BE decreases. When the difference between the variances exceeds 
0.02 this probability represents the probability of type I error, and it is always 0.05 for the 
smallest sample size of 25. For larges sample sizes the probability of type I error is lower 
than 0.05 only when the difference between variances is greater than 0.05. 
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Table 2. Size* of the test,  
  Ignoring correlation in  ,  0P Cp   
Accounting for correlation in  , 
 P Cp   
R  T  n=25 n=50 n=100 n=25 n=50 n=100 
-0.2 -0.2 0.0100 0.0000 0.0000 0.0133 0.0033 0.0133 
 0 0.0000 0.0067 0.0000 0.0000 0.0067 0.0267 
 0.2 0.0067 0.0000 0.0000 0.0067 0.0133 0.0400 
 0.4 0.0033 0.0000 0.0033 0.0167 0.0133 0.0233 
 0.8 0.0000 0.0067 0.0100 0.0200 0.0300 0.0267 
0 -0.2 0.0033 0.0133 0.0133 0.0033 0.0133 0.0133 
 0 0.0033 0.0200 0.0100 0.0033 0.0200 0.0100 
 0.2 0.0033 0.0133 0.0333 0.0033 0.0133 0.0333 
 0.4 0.0000 0.0133 0.0100 0.0000 0.0133 0.0100 
 0.8 0.0100 0.0167 0.0300 0.0100 0.0167 0.0300 
0.2 -0.2 0.0100 0.0000 0.0133 0.0067 0.0000 0.0100 
 0 0.0000 0.0467 0.0567 0.0000 0.0167 0.0233 
 0.2 0.0133 0.0267 0.0467 0.0100 0.0133 0.0067 
 0.4 0.0133 0.0467 0.0767 0.0067 0.0267 0.0233 
 0.8 0.0500 0.0667 0.1433 0.0233 0.0133 0.0433 
0.4 -0.2 0.0033 0.0000 0.0100 0.0033 0.0033 0.0133 
 0 0.0000 0.0067 0.0333 0.0000 0.0000 0.0200 
 0.2 0.0067 0.0333 0.0667 0.0033 0.0200 0.0167 
 0.4 0.0100 0.0467 0.1300 0.0067 0.0133 0.0067 
 0.8 0.0533 0.1700 0.3700 0.0100 0.0233 0.0167 
0.8 -0.2 0.0000 0.0000 0.0000 0.0067 0.0333 0.0333 
 0 0.0000 0.0000 0.0000 0.0067 0.0100 0.0200 
 0.2 0.0000 0.0000 0.0000 0.0067 0.0133 0.0033 
 0.4 0.0000 0.0000 0.0000 0.0033 0.0067 0.0333 
 0.8 0.0133 0.1100 0.2867 0.0000 0.0000 0.0200 
 *the probability of rejecting the null hypothesis of ―not bioequivalent‖ at the 
boundary of the BE region. 
 R  and T are correlations among reference measures and among test measures. 
  Bold italic: 95% CI does not include 0.05; Bold: 95% CI includes 0.05. 
 
 
 
 
 
 
 63 
 
Table 3: Effect of misclassification of the rule theta on Type I error 
 
Sample 
Size 
rhoR rhoT .2  0  .2  .4  .8  
25 -0.2 -0.2 0.0063 0.0063 0.0025 0.0000 0.0000 
0 0 0.0163 0.0063 0.0013 0.0013 0.0013 
0.2 0.2 0.0263 0.0063 0.0063 0.0013 0.0000 
0.4 0.4 0.0350 0.0050 0.0088 0.0050 0.0013 
0.8 0.8 0.0638 0.0025 0.0125 0.0088 0.0025 
50 -0.2 -0.2 0.0125 0.0125 0.0000 0.0000 0.0000 
0 0 0.0475 0.0138 0.0088 0.0038 0.0000 
0.2 0.2 0.0875 0.0125 0.0125 0.0050 0.0000 
0.4 0.4 0.1213 0.0113 0.0238 0.0113 0.0038 
0.8 0.8 0.2388 0.0113 0.0588 0.0388 0.0113 
100 -0.2 -0.2 0.0188 0.0188 0.0000 0.0000 0.0000 
0 0 0.0838 0.0163 0.0050 0.0025 0.0000 
0.2 0.2 0.2100 0.0113 0.0113 0.0025 0.0000 
0.4 0.4 0.3488 0.0088 0.0375 0.0088 0.0025 
0.8 0.8 0.5288 0.0238 0.1313 0.0663 0.0238 
2 2 2 2ln(1.25); 0.04; 0.061 1 2 2 1 2 1 2T R T R R R T T
                
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Table 4. Power of the test 
        
  Ignoring correlation in  , 
 0P Cp   
Accounting for correlation in  , 
 P Cp   
rhoR muT-
muR 
n=25 n=50 n=100 n=25 n=50 n=100 
-0.2 -0.335 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
 -0.223 0.0033 0.0100 0.0167 0.0133 0.0283 0.0567 
 -0.112 0.1600 0.5100 0.9017 0.2683 0.6950 0.9800 
 0 0.4183 0.9017 1.0000 0.5917 0.9633 1.0000 
 0.112 0.1567 0.5483 0.8967 0.2567 0.7450 0.9717 
 0.223 0.0050 0.0050 0.0167 0.0067 0.0283 0.0600 
 0.335 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0 -0.335 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
 -0.223 0.0250 0.0467 0.0833 0.0250 0.0467 0.0833 
 -0.112 0.1933 0.6283 0.9350 0.1933 0.6283 0.9350 
 0 0.4333 0.9200 0.9983 0.4333 0.9200 0.9983 
 0.112 0.2250 0.5850 0.9417 0.2250 0.5850 0.9417 
 0.223 0.0183 0.0383 0.0817 0.0183 0.0383 0.0817 
 0.335 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
0.2 -0.335 0.0000 0.0017 0.0000 0.0000 0.0017 0.0000 
 -0.223 0.0300 0.0817 0.1850 0.0183 0.0350 0.0783 
 -0.112 0.2167 0.6683 0.9583 0.1467 0.5017 0.8983 
 0 0.4367 0.9133 1.0000 0.3383 0.8367 0.9917 
 0.112 0.2267 0.6767 0.9650 0.1600 0.5383 0.9083 
 0.223 0.0383 0.1150 0.2133 0.0250 0.0533 0.0850 
 0.335 0.0017 0.0000 0.0000 0.0017 0.0000 0.0000 
0.4 -0.335 0.0000 0.0017 0.0017 0.0000 0.0000 0.0000 
 -0.223 0.0350 0.1383 0.3367 0.0150 0.0283 0.0867 
 -0.112 0.2333 0.7167 0.9717 0.1233 0.4817 0.8567 
 0 0.4350 0.9283 1.0000 0.2467 0.7500 0.9800 
 0.112 0.2567 0.7667 0.9683 0.1333 0.4733 0.8383 
 0.223 0.0350 0.1500 0.3100 0.0150 0.0383 0.0767 
 0.335 0.0000 0.0033 0.0017 0.0000 0.0000 0.0000 
0.8 -0.335 0.0117 0.0117 0.0133 0.0017 0.0017 0.0000 
 -0.223 0.0483 0.2467 0.5850 0.0067 0.0600 0.0917 
 -0.112 0.2817 0.7533 0.9783 0.0817 0.3633 0.7633 
 0 0.4517 0.9133 1.0000 0.1650 0.6250 0.9300 
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 0.112 0.2833 0.7500 0.9833 0.0750 0.3517 0.7700 
 0.223 0.0683 0.2250 0.5600 0.0150 0.0317 0.0883 
 0.335 0.0033 0.0150 0.0200 0.0000 0.0000 0.0000 
 2 2 0.04
1 2R R
   , 2 2 0.05
1 2T T
   , R T  and  R T   
 power of test = the probability of rejecting the null hypothesis ―not 
bioequivalent‖ within the population  BE region 
 
 
Table 5. Power of the test as a function of the correlation, difference in the 
variances, and the sample size 
rhoR 2 2
T R
  V1T 
Ignoring correlation in  , 
 0P Cp   
Accounting for correlation in  , 
 P Cp   
  N=25 n=50 n=100 n=25 n=50 n=100 
-0.2000 0.0000 0.6300 0.9867 1.0000 0.7700 1.0000 1.0000 
 0.0100 0.4183 0.9017 1.0000 0.5917 0.9633 1.0000 
 0.0200 0.2100 0.6700 1.0000 0.3033 0.8567 1.0000 
 0.0300 0.1133 0.3967 0.8133 0.1967 0.6333 0.9467 
 0.0400 0.0400 0.1800 0.5433 0.1000 0.3333 0.8067 
 0.0600 0.0100 0.0333 0.0400 0.0200 0.0533 0.2300 
0.0000 0.0000 0.6733 0.9933 1.0000 0.6733 0.9933 1.0000 
 0.0100 0.4333 0.9200 0.9983 0.4333 0.9200 0.9983 
 0.0200 0.1867 0.7200 0.9735 0.1867 0.7200 0.9735 
 0.0300 0.0867 0.3967 0.8167 0.0867 0.3967 0.8167 
 0.0400 0.0567 0.1667 0.4933 0.0567 0.1667 0.4933 
 0.0600 0.0033 0.0200 0.0833 0.0033 0.0200 0.0833 
0.2000 0.0000 0.7633 0.9933 1.0000 0.6667 0.9800 1.0000 
 0.0100 0.4367 0.9133 1.0000 0.3383 0.8367 0.9917 
 0.0200 0.1933 0.6167 0.9700 0.1133 0.5000 0.9133 
 0.0300 0.1067 0.4533 0.8033 0.0700 0.2933 0.6333 
 0.0400 0.0367 0.2300 0.5100 0.0233 0.1433 0.3000 
 0.0600 0.0033 0.0133 0.0733 0.0000 0.0067 0.0233 
0.4000 0.0000 0.6633 0.9900 1.0000 0.4700 0.9567 1.0000 
 0.0100 0.4350 0.9283 1.0000 0.2467 0.7500 0.9800 
 0.0200 0.2000 0.7167 0.9767 0.1067 0.4500 0.8633 
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 0.0300 0.0700 0.4200 0.8233 0.0267 0.1900 0.4900 
 0.0400 0.0500 0.1700 0.5533 0.0200 0.0733 0.1667 
 0.0600 0.0133 0.0333 0.0733 0.0000 0.0100 0.0033 
0.8000 0.0000 0.6967 0.9933 1.0000 0.4133 0.8900 1.0000 
 0.0100 0.4517 0.9133 1.0000 0.1650 0.6250 0.9300 
 0.0200 0.2467 0.7067 0.9800 0.0733 0.2933 0.6633 
 0.0300 0.0833 0.3967 0.8333 0.0200 0.0867 0.2800 
 0.0400 0.0567 0.2467 0.4533 0.0033 0.0400 0.0633 
 0.0600 0.0033 0.0433 0.0600 0.0000 0.0000 0.0000 
 
Table 6. Percentage of the simulated cases leading to correct decision regarding BE. 
  MV BE criterion accounting for the correlation 
  BE  Not BE 
  Incorrect correct Total  Incorrect correct Total 
Intersection of 2 
(1 / 2)CI Univariat
e tests (Bonferoni 
correction) 
Incorrect 3.5 15.56 19.07  11.87 0.91 12.78 
Correct 0.37 80.56 80.93  12.29 74.93 87.22 
Total 3.88 96.12 100  24.16 75.84 100 
         
Intersection of 2 
(1 )CI Univariate 
tests 
 
 
Incorrect 3.23 7.81 11.04  15.84 1.72 17.56 
Correct 0.65 88.31 88.96  8.33 74.11 82.44 
Total 3.88 96.12 100  24.16 75.84 100 
         
MV ignoring 
correlation in rule 
 
 
 
Incorrect 0.9 0.52 1.43  22.66 11.04 33.71 
Correct 2.97 95.6 98.57  1.5 64.79 66.29 
Total 3.88 96.12 100  24.16 75.84 100 
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Figure 4. Power as a function of mean of the test variable 
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Figure 5. Effect of the sample size and the variance of the test variables on Power 
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Table 7. Effect of the reference and the test correlations on multivariate PBE criterion (Cp) as a function of  0  
R  T  
-0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
-0.2 + + + + + + + + + + + + 
-0.1 + + + + + + + + + + + + 
0 = = = = = = = = = = = = 
0.1 - - - - - - - - - - - - 
0.2 - - - - - - - - - - - - 
0.3 - - - - - - - - - - - - 
0.4 + + - - - - - - - - - - 
0.5 + + + - - - - - - - - - 
0.6 + + + + + - - - - - - - 
0.7 + + + + + + + - - - - - 
0.8 + + + + + + + + + - - - 
0.9 + + + + + + + + + + + - 
: ,  : ,  : ,  0 0 0
 is  under no correlation in both reference and test, 3.48970 0
     
  
     

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4.5.3 Asymmetry of test 
The upper bound of the multivariate BE region, , were calculated according to 
the correlations between the test, columns in Table 7, and between the reference, rows in 
the table. The calculated  ‘s were  compared to 0 , which was calculated assuming 
independence between the test variables, and independence between the reference 
variables. The difference between these two   ‘s represents the difference between the 
BE regions under correlation and under independence. The ‗+‘ represents the condition 
where the BE region is larger under correlation, while the  ‗-‗ represents the condition 
when the BE region was larger under independence. The equal sign represents equal BE 
regions under both conditions. The diagonal of Table 7 represents the conditions where 
the reference correlations are equal to the test correlations. The table is clearly 
asymmetric, because its entries are not mirror images across the diagonal. This means 
that the BE regions are not equal for the same combinations of correlations depending on 
which drug is considered the reference. This is due to the scaling of the MV PBE 
criterion by the reference variance. This results in the possibility of considering a drug A 
as bioequivalent to a drug B, while Drug B is not bioequivalent to drug A.  
  
4.6. Graphing the BE regions 
To graphically illustrate the nature of the regions of equivalence consider the 
following. As before, let TX and RX be vectors of random variables representing the 
metrics used.  Let TX be distributed as multivariate normal with mean vector Tμ and 
variance covariance matrix TΣ . Let RX be distributed as multivariate normal with mean 
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vector Rμ and variance covariance matrix RΣ . Then, as described in chapter, section 2.3 
bioequivalence acceptance region is defined as  
      1 1 .C trace pp T R T R R T R       Σ Σ μ μ Σ μ μ  (37) 
Note that this could be rewritten, 
      1 1 .p traceT R R T R T R     μ μ Σ μ μ Σ Σ  (38) 
The right hand side of this inequality, which is a scalar, does not depend on the 
means. Therefore, the left hand side is a quadratic form in terms of the difference of the 
mean vectors and thus the inequality represents an ellipsoid whose shape is controlled by 
the variance covariance matrices (Johnson and Wichern 2002). Similarly we could 
construct an ellipsoid based on the estimates of the parameters on both LHS and RHS of 
the equation above, say, using  ˆ 95C Cp p .  This ellipsoid is formed by the inequality, 
      1 1ˆ ˆ ˆˆ ˆ ˆ ˆ 95C p traceT R R T R p T R     μ μ Σ μ μ Σ Σ . (39) 
Then, graphically one could conclude bioequivalence if the ellipsoid based on the 
95% region of the data (equation 39) is totally contained within the ellipsoid defined by 
the . In Figure 6 examples of these ellipsoids are presented. The red ellipse represents 
the BE acceptance region constructed under the FDA defined conditions for two 
independent variables. The blue ellipse represents the area of the data bounded by the 95
th
 
percentiles of the two independent variables.  The black ellipse represents the BE 
acceptance region under correlated variables. Finally, the gold ellipse represents the area 
of the data bounded by the 95
th
 percentiles of the two correlated variables. The overlap of 
these ellipses demonstrates how accounting for the correlation between the variables 
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actually changes the acceptance region. This result could be vastly different depending on 
how the correlation is incorporated. For example, area in the figure that is outside the BE 
region that ignores correlation (red ellipse) is actually within the bioequivalence region 
that accounts for the correlation (the black ellipse). On the other side there are areas 
within the region that ignores correlation but they are outside the BE regions defined 
under correlation. 
Figure 6 Acceptance bioequivalence regions 
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5 Multivariate Extensions of Population Bioequivalence: A Comparison 
Between three Measures 
 
5.1.  Abstract 
In this article an extension of the univariate methods for evaluating the population 
bioequivalence (PBE) of a generic drug to a pre-licensed drug, or the bioequivalence of 
two formulations of a single drug is extended to simultaneously test for multiple 
correlated pharmacokinetic metrics. Specifically the univariate criterion recommend by 
the food and drug administration (FDA) is extended. One of the extensions proposed in 
the literature (Chervoneva, 2007), attempts to extend the univariate PBE through the use 
of the trace of the matrix of variances covariances of the pharmacokinetic measures. 
However, the trace, being the sum of the diagonal elements, does not incorporate the 
covariance. Dragalin et al. (2003) proposed a multivariate criterion using the Kullback–
Leibler divergence (KLD) as a measure of discrepancy between the distributions of the 
two formulations. This criterion does not reduce to the univariate criterion proposed by 
the FDA, because it is not scaled by the reference variance. 
The extension proposed here, similar to the univariate PBE, uses an inequality in 
quadratic forms. A parametric bootstrap method is used to determine the  1  100% 
critical point of the distribution of the quadratic form. The performance of the proposed 
multivariate criterion is evaluated through a simulation study. The results from a 
simulation study and an application of this method are presented. The three criteria are 
compared by a simulation and applications. 
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5.2. Key words 
multivariate bioequivalence; population bioequivalence; AUC; Cmax  
 
5.3. Introduction  
Bioequivalence studies are used in the development of generic drugs and the 
development of new formulations of drugs that were previously approved. Developing a 
new drug and obtaining approval from the Food and Drug Administration (FDA) requires 
multiple clinical trials to document the toxicity and the efficacy of the pharmacologically 
active ingredients of the new drug. A generic formulation of an approved compound is 
not subject to the multiple clinical trial requirement of a new compound because it is 
assumed that the active ingredients of the generic drug have the same toxicity and 
therapeutic efficacy as the approved drug. Thus, a generic must only demonstrate 
bioequivalence to the approved drug; once bioequivalence is demonstrated, it is also 
assumed that the therapeutic efficacy is similar between the approved and generic drugs. 
Thus the bioequivalence studies are designed to establish this expected similarity of the 
approved drug to the generic drugs having the same active ingredients.  
Several pharmacokinetic metrics are used to quantify bioavailability. Experiments 
are designed to measure the concentration of the active ingredient in the biological active 
site, like blood, at appropriate time intervals. A profile of the concentration of the drug 
over time is then generated. The pharmacokinetic metrics, specifically, AUC , the 
maximum absorbed, maxT  the time at which maxC occurs, rates of absorption, rate of 
elimination, and blood or plasma half lives are calculated. 
For any given metric two drugs are defined to be bioequivalent if  
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2  , (40) 
where   is a predefined constant, and for any given metric,  is a critical value obtained 
from the distribution of a distance function of the new and the reference drugs. The upper 
limit   is often prescribed by regulatory agencies. For example, the US FDA‘s guideline 
suggests   should be 20% of the reference mean. The  is estimated from the data and is, 
in general, the (1 - 2 )th percentile of the distribution of the distance function for a given 
confidence level  . If 
2 satisfies the inequality above the two drugs are considered 
bioequivalent.  For instance, if the 90% confidence interval of the distance function falls 
completely within the interval  ,  , bioequivalence is concluded. This procedure is 
equivalent to testing two one-sided hypotheses each at level  using  an analogous test 
(Schuirmann, 1987).   
The average bioequivalence (ABE) test focuses on the differences in the means of 
the pharmacokinetic parameters. This method of evaluating bioequivalence, does not 
account for differences in the variability between the reference and test drugs. Population 
bioequivalence (PBE) was proposed to evaluate prescribability of the drug. 
Prescribability of a drug is defined as the ability to get the same effect by prescribing the 
brand-name drug or its generic drug to a new patient (Chow and Liu, 1992). In contrast to 
average BE, the PBE includes comparisons of the means and the total variability of the 
pharmacokinetic measures between the reference and test drugs (Hauk and Anderson, 
1992).  
The PBE was introduced by FDA in 1997 as an alternative method of testing BE. 
The PBE is a measure of the distance between the test and reference distributions with 
respect to the first two moments while the ABE is simply the difference between the first 
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moments only. The PBE may be thought of as the ratio of two expected squared distances 
where the numerator is the expected squared distance between the reference and the test 
and the denominator is the expected squared distance between two reference 
observations. Bioequivalence, then is determined by the ratio of the two expected squared 
differences is within a predefined distance, , from unity. That is,  
 
 
 
2
1
2
E y yT R
E y yR R

 
    
    
 (41) 
where yT  is a random variable denoting the test PK metrics, yR and yR are two 
realizations of the reference random variable and E represents the expectation.  
The univariate PBE criterion in (41), by substituting the unit ratio of the 
denominator term for the 1, could be redefined as (Sheiner 1992, Schall and Luus  1993), 
 
   
 
2 2
2
2
E y y E y yT R R R
E y yR R

             
    
. (42) 
Rewriting Eqn (42) in terms of the population mean and variance, it reduces to, 
 
 2 2 2
2
T R T RC
R
   


  
  . (43) 
where R and T are the means of the reference and the test random variables 
respectively, and 2
R
 and 2
T
 are the population variances of the reference and test 
pharmacokinetics respectively. Thus, the 
2 from the original inequality in (40)  is a 
function both of a distance metric of the means as well as the variances. The hypothesis 
test form of PBE uses the hypotheses 0 :  vs :aH C H C   . Bioequivalence is 
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concluded with  1  x100% confidence if (1 )Cˆ    , where (1 )Cˆ  is the estimate of 
the upper limit of the one-sided (1 )100th confidence interval of the PBE criterion 
defined in (43) using the maximum likelihood estimates (mle‘s) of the means and 
variances. 
Extending this to more than one metric requires accommodation of the 
correlation. For example, suppose that the blood absorption coefficient ( aK ), and the 
time ( maxT ) until the maximum concentration ( maxC ) of the blood concentration is 
reached, and the area under the blood concentration curve ( AUC ), are all calculated from 
the same blood concentration-time profile. In this case, the assumption of independence 
in testing bioequivalence using multiple tests for each of the four parameters is not 
justifiable. Clearly, the correlations among these variables should be incorporated in the 
multivariate tests of bioequivalence. 
Multiple multivariate extensions for the average BE (Brown, 1995; Berger and 
Hsu, 1996; Brown, 1997; Munk and Pflujer, 1999; Wang, 1999; and Tamhane and 
Logan, 2004) have been proposed in the literature. However, there are few that deal with 
the multivariate PBE. . The first notable exception  is  Dragalin et al. (2003), in which the 
Kullback–Leibler divergence (KLD) is used as a measure of discrepancy between the 
distributions of the two formulations. They propose a generalization of average and PBE 
measures, and generalized it to the multivariate situation. Their multivariate method 
could be summarizes as follows. Consider a multivariate random variable Y representing 
a set of PK metrics. Suppose Y is distributed as normal with mean vector μ  and variance 
covariance matrixΣ . Let T and R represent treatment and reference groups, respectively. 
Dragalin et al. (2003) propose a criterion based on the following inequality 
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    1 1 1 22D trace pp T R T R T R T R                 μ μ μ μ Σ Σ Σ Σ  (44) 
Here, the left hand side (LHS) of the equation is the KLD. Two formulations are 
declared bioequivalent if the upper bound of a level-  confidence interval for the KLD 
is less than a given specific value, . This criterion does not reduce to the univariate 
criterion proposed by the FDA in equation (43); instead it reduces to 
 
   2 22 2 2 21
2 22
T R T RT R R TDp
R T
       
 
      
  
 
  
 (45) 
Thus, this criterion may be seen as the average of two terms where the first term is the 
same measure of distance scaled by the reference variance proposed by FDA. The second 
term is similar except that it is scaled by the variance of the test. This criterion is 
equivalent to the FDA proposed criterion only if the reference and test variances are 
equal, and then it is only a measure of the squared mean distances and not the differences 
of the variances. Dragalin et al. (2003) only proposed the multivariate criterion, but never 
tested it.  
The second notable exception is Chervoneva et al. (2007) in which they propose a 
criterion for the p-variate multivariate case using the trace of the variance-covariance 
matrices. Although this criterion reduces to the univariate PBE when p = 1, it is not an 
appropriate extension to the multivariate case as the method fails to incorporate the 
correlations. The trace of the matrices, (the sum of the diagonal elements of the 
covariance matrix), ignores the correlations.   
The bioequivalence rule proposed by Chervenova el al. (2007) is, 
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       
 
tr trT R T R T R
Bp
tr R

   
 
μ μ μ μ Σ Σ
Σ
 (46) 
 
In applications they propose constructing a 95% confidence interval for Bp , and deem 
the test and reference distributions bioequivalent when the upper limit of this interval is 
less than the predefined  . For p = 1 this rule reduces to the univariate rule in equation 
(43).  
The objective of this study was to develop a multivariate PBE criterion that is equivalent 
to the univariate criterion approved by the FDA, then comparing the three criteria in 
testing PBE in a simulation and using examples. The following sections the development 
of the new criterion are discussed and a standardized method to compare between them is 
outlined. More detailed discussion of the properties of the newly developed criterion will 
be presented.  
5.4. Methods 
5.4.1 Development of the multivariate bioequivalence criterion C p  
The proposed multivariate extension is based on the fundamental definition of the 
PBE. That is, the difference in the means and the difference in the variances are scaled by 
the reference covariance matrix and summed. The criterion is given as follows: 
      1 1C trace pp T R T R R T R       Σ Σ μ μ Σ μ μ  (47) 
To justify this let TY and RY be p-variate random variables denoting the test and 
reference PK metrics. Assume, TY is distributed as a p-variate normal with mean vector 
Tμ  and variance covariance matrix TΣ . And let RY  and RY be two realizations of the 
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p-variate normally distributed random variable with mean Rμ  and variance covariance 
matrix RΣ .  
The multivariate extension proposed here basically extends the definition (42) for 
the univariate case. The squares in (41) are replaced by quadratic forms and the 
denominator is replaced by its multivariate equivalent, namely the inverse of the 
corresponding matrix 
   
1
2
ER R R R R
      
Σ Y Y Y Y . (48) 
Then the multivariate expression similar to (42) is as follows: 
        1 1C E Ep T R R T R R R R R R
                 
Y Y Σ Y Y Y Y Σ Y Y  (49) 
Substituting  1 2R T R
 Z Σ Y Y ; and  1 2R R R

 K Σ Y Y  in (49), and using the 
matrix and trace properties, the multivariate criterion in (49) could be expressed as  
            C trace E E trace E Ep     Σ Z Z Σ K KZ K  (50) 
 
It can be shown that the expectation of Z is equal to  1 2R T R
 Σ μ μ , and its variance 
covariance matrix is 1 2 1 2R T R
  Σ Σ Σ I , the expectation of K is 0 , and its variance 
covariance matrix ΣK is equal to 2I , where I is a p p  identity matrix (see Appendix 
B). Substituting these expectations and variance covariance matrices in  (50) reduces to 
the multivariate criterion in (47) (Dahman 2009 Ch3 for details).  
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It is simple to show that the resultant multivariate criterion reduces to the 
univariate criterion (43) when p=1. It also accounts for the total variability and the 
correlations among the PK metrics used in evaluating bioequivalence. 
Using the invariance property, the maximum likelihood estimator of the 
multivariate PBE criterion could be estimated from the data as: 
      1 1ˆ ˆ ˆ ˆˆ ˆ ˆ ˆC trace pp T R T R R T R     Σ Σ μ μ Σ μ μ , (51) 
where ˆTμ  and ˆ Rμ are the maximum likelihood estimates (mle‘s) of the population 
means, and ˆ TΣ  and 
ˆ
RΣ are mle‘s of the variance covariance matrices of the test and 
reference variables.  
 
5.4.2 Constructing the100(1 )th confidence interval of the MV criteria 
The exact distribution of the MV criteria introduced earlier, Bp , Dp , and C p are not 
tractable. Therefore, a parametric bootstrap method (Efron & Tibshirani, 1993), as 
recommended by the FDA, is proposed. This method requires obtaining the mle‘s of the 
population parameters Tμ and TΣ of the test and Rμ and RΣ of the reference metrics. 
Random samples of the same size as the original experiment would be generated from 
multivariate normal distribution with means and variances equal to the mle‘s of each of 
the drugs in the original experiment. The MV population criteria would be calculated for 
each of the bootstrap samples. Then the100(1 )th percentile of the distribution of 
criteria based on the B bootstrap samples would be determined. PBE is concluded if the 
100(1 )th percentile is less than the predefined limit,  .  
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5.4.3 Specifying the upper limit, , of BE 
 In the univariate case,  is defined according to predetermined limits determined 
by the FDA. The maximum difference between the variances of the test and the reference 
( 2 2
T R
  ) allowed by FDA (1997) is 0.02, and the minimum allowed variance of the 
reference ( 2
R
 ) is 0.04. 
These limits are extended to the multivariate criterion, by setting the maximum 
difference between the means of the test and reference pharmacokinetic measures as the 
natural logarithm of 1.25; the maximum difference between the test and reference 
variances as 0.02, and the lowest variances as 0.04. Since there is no analogous guideline 
for incorporating the correlations, different combinations of correlations among the test 
and reference variables and will be used. The value of   depends on the PBE criterion 
used. This value would not depend on the correlation for Chervenova's, so it is always 
constant. 
Using the proposed multivariable limits, values of   were calculate for the case 
where  p = 2 with the BE limits of means and variance differences as defined by FDA. 
Dahman (2009) have shown that the upper limit of the acceptance region of BE,
 
 , is 
affected by the number of parameters, the correlations of test and by the correlations of 
reference. When these correlations are identical, the bigger the correlation the smaller is 
 (data not shown). When the correlations are negative, the value of   is always greater 
than 0 . On the other hand, when the correlations are positive, as expected among PK,   
is always smaller than 0 . Dahman (2009) demonstrated that this variability in the values 
of  affects the results of testing the hypothesis of bioequivalence. This phenomenon 
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affects both criteria that account for the correlation, i.e. Dp  and C p . This will require the 
regulatory bodies to study the conditions and effect of the values of the correlations to set 
the values of the predefined upper limit of the population criterion.  
5.5. Properties of the multivariate PBE criterion C p   
Properties of the multivariate PBE criterion C p proposed in the previous sections 
are studied using Monte-Carlo simulation methods. The simulation study was designed to 
evaluate the distribution of the proposed multivariate criterion C p  under different 
combinations of sample size (number of subjects in the trial), differences in the averages 
and variances of the pharmacokinetic (PK) parameters between the reference and test 
drugs, and under different correlations between the PK parameters within each treatment 
group. This study was mainly designed to guide in the selection of a method to construct 
the confidence interval for the proposed criterion. Another simulation study was designed 
to study the size and power of the hypothesis tests, and to compare the multivariate 
criterion versus the multiple testing using the univariate criteria. 
These studies were limited to equal size samples of reference and test drugs. The effect of 
different sample sizes, missing values and dependence between the treatments drugs 
should be tested in future studies. 
 It has been shown in many studies that the log-transformed pharmacokinetic 
parameters have a normal distribution, and that data extracted from the same 
concentration time profiles for each subject are correlated. To create samples that 
preserve these properties we used random sampling from multivariate normal 
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distribution. A sampleY of N sets of two pairs of variables was generated by random 
selection from a 4-variate normal distribution.  
The first pair of variable &
1 2
y y
R i R i
represent the log-transformed pharmacokinetic 
parameters of the reference group, namely log( )maxC and log( )AUC . The second pair 
&
1 2
y y
T i T i
represent the log-transformed data of the test group, where i  represents the 
thi subject, 1,...,i N . Each pair has a bi-variate normal distribution, which we will 
denote by ~ ( , )Y Nk p kk
  , where k is the treatment, and the population means vector 
for each treatment is  ,1 2k kk   and k is the variance covariance matrix for each 
treatment.  
 SAS IML code calling the function (VNORMAL) was used in a macro to 
generate the samples of p-variate normal data. All simulations and analyses were done 
using macros in SAS 9.2, SAS Institute, Cary, NC.   
 The distribution of C p is not known, and cannot be easily determined. The FDA  
recommended using the parametric bootstrap method to construct the confidence interval 
for the univariate PBE criterion rather than applying a normal approximation. It was 
concluded that similar to the univariate case, using the parametric confidence intervals 
which assume normality for the multivariate PBE criterion C p  would not be appropriate. 
In order not to assume any distribution the parametric bootstrap method to evaluate the 
percentile confidence interval was used as suggested by the FDA. The parametric 
bootstrap method was used because there is enough evidence that the log-transformed 
pharmacokinetic measures like AUC, maxC and maxT  follow a normal distribution. For 
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that reason it is convenient to resample (for the bootstrap) from a p-variate normal 
distribution in which means and variance covariance matrix are equal to those estimated 
from the sample.  
 
 The non-parametric confidence interval was constructed using the percentiles 
from the parametric bootstrap method. From each replication of the experimental 
settings, the means and the variance covariance matrices were estimated. Then 2000 
bootstrap samples were generated by randomly selecting from multivariate normal 
distribution with mean and variance equal to those estimated from the replication. Then 
estimates of the multivariate PBE criterion Cˆp were calculated for each of these 2000 
bootstrap samples. The 95
th
 bootstrap percentile of Cˆp was determined. This is the upper 
limit of the one sided 95% confidence interval for Cˆp that would be used in the 
hypothesis testing.  
 
5.5.1 Simulation Configurations 
The simulation study was run with 500 replicates. Each replicate represented a 
bioequivalence trial with N subjects in each group (treatment or reference). For each 
subject two measures representing the log-transformed AUC and maxC , were selected 
from the p-variate normal distribution as described earlier. To estimate the nonparametric 
confidence interval in each simulation, 2000 bootstrap samples were randomly selected 
from the p-variate distributions. Efron (1982) demonstrated that in general 2000 bootstrap 
samples would be large enough to obtain unbiased confidence interval. 
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Following FDA guidelines for the univariate case of PBE, and based on the 
information from published bioequivalence trials several factors were considered at 
specific levels. It is important to evaluate the performance of any new statistic or test 
under a variety of sample sizes. The usual number of subjects in most of the 
bioequivalence drug trials varies between 20 and 100 per group. Three sample sizes were 
chosen (25, 50 and 100). As discussed earlier the maximum allowable difference between 
the (log transformed) means of the test and the reference parameters is ln(1.25). the 
difference in the means was test at 5 values (-2ln(1.25),  -ln(1.25)/2, 0, ln(1.25), 
2ln(1.25)). As recommended by the FDA, the minimum value for the reference standard 
deviation of 0.2 was set as the value for the variance of the reference pharmacokinetics. 
The difference in the variance between the variances of the reference and the test 
pharmacokinetic were selected from 0.04, 0.06 and 0.1. The correlations between 
variables were not used in the definition of bioequivalence by the FDA or the previous 
methods of testing multivariate PBE. The performance of the proposed criterion was 
evaluated under a wide range of correlations that allow for all possible values including 
rare cases  of negative correlations. The effects of the correlations between -0.2 and 0.8 in 
increments of 0.2 on the power and the size of the tests for bioequivalence were 
evaluated.  
The size of testing the hypotheses of BE was evaluated under conditions that 
represent the maximum allowable values of variances and differences between the means 
of the reference and test drugs. The power of the test was evaluated under conditions that 
fulfill the BE with respect to the variances and the means. The size and power were 
 87 
 
evaluated under different sample sizes and variable correlations between the reference 
and between the test variables.  
 
5.5.2  Description of the simulation steps 
The simulation performed the same steps for each of the combinations of sample size, 
difference in means, difference in variance and correlations between the reference and the 
correlations between the test PK measures. Five hundred samples (replicates) of 4 
random variables of size N were generated from a multivariate normal distribution with 
reference means  1R  and 2R  and test means 1T and 2T , and correlations R and 
T  and variances 
2
1R
 , 2
2R
 , 2
1T
 , and 2
2T
 that define each configuration or setting. 
The mean and variance were estimated for each replication. Each replication was 
bootstrapped by randomly selecting 2000 from multivariate normal distribution with the 
means and variances equal to those estimated for each replication. The MV criterion 
Cˆp was calculated fro each bootstrap sample. The 95
th
 percentile for the 2000 calculated 
bootstrap estimates of Cˆp  was determined for each replication. For each replication, BE 
was determined if the upper limit of the one-sided 95% confidence interval for Cˆp  was 
less than the predefined  . The number and percent of times the result was correct in 
agreement with the setting were calculated using the multivariate criterion and using the 
univariate criterions for each of the variables. The size and power of the tests were 
calculated by calculating the percentage of times the null hypothesis was rejected among 
the 500 replicates, if the null hypothesis was true or was not true respectively. 
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5.5.3  Simulation Results 
The size of the test was evaluated using random selection from distributions that 
have the maximum accepted values of the differences between the means and between 
the variances. These values define the boundaries of the multivariate PBE acceptance 
region in all dimensions. These are the values that define the true value of the 
multivariate PBE criterion as equal to the predefined  . The table compares between two 
tests, the first accounts for the correlation in the predefined  , the second one ignores the 
correlations when predefined  . The type I error are very conservative in the case of 
smallest tested sample sizes of 25, these errors increase by increasing the sample size. 
These errors never exceed the 0.05 level except in higher correlations than 0.2 between 
the reference measures, when using the theta that ignores the correlations. The largest 
type I errors are observed when the correlations of either the reference or the test are very 
high (0.8), and when the differences between the correlations of the reference and the 
correlations among the test are large. 
Probability of the type I errors are also sensitive to the magnitude of the 
correlation used in calculating the  . Testing the bioequivalence hypothesis using 
negative correlations, on samples drawn from positively correlated random variables, 
causes the highest increase in type I errors. There is a minimal increase in probability of 
Type I error when using a positive correlation that is not equal to the true correlation 
except for testing with lower correlations when the true correlation is high 0.8. This 
would result in rejecting the null hypothesis, and concluding PBE in more non-BE cases.  
As expected the power power of the proposed multivariate PBE test was highest 
when the two true means of the reference and test variables were equal. The power drops 
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gradually as the difference between the means increases in either direction. Accounting 
for the correlation in the upper limit theta, , of PBE result in a test with less power than 
ignoring the correlation. The power increases as the absolute difference between the test 
and reference means increases. The test that ignores the correlation achieved the highest 
power, while the test that utilized the intersection of two separate univariate tests was 
with the smallest power. The power increases as the sample size increases and as the 
difference between the variances decreases,  
Each simulation sample was classified as bioequivalent or not according to the 
proposed multivariate PBE test accounting for correlations, ignoring the correlations, and 
using the intersection of two univariate tests of BE with and without Bonferoni 
correction. Then according to each scenario the simulation samples were classified into 
correctly classified and incorrectly classified. Table 8 compares the correct classification 
of all BE and non-BE scenarios using those 4 methods. Ignoring the correlation is 
superior to all other tests in classifying the scenarios correctly when the truth is BE. 
However this superiority is at the cost of having the highest proportion of 
misclassification (Incorrect Classification) when the truth is not BE.  
The power function was evaluated as a function of the mean of test drug under 
fixed values of the reference means and variance covariance matrix and under equal 
correlations between the test variables and between the reference variables. The power of 
rejecting the null hypothesis of ―no BE‖ is higher than 0.9 when the reference means are 
equal to the test means. This power decreases as the difference increases. The power of 
testing the null hypothesis of ‗no BE‘, under fixed variance of the reference, drops as the 
difference between the variances of the test and reference increases. This power increases 
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by the sample size as expected. The power is above 0.7 with sample size of 100 when the 
difference is smaller that 0.02.  
 
Table 8 Percentage of cases classified correctly/incorrectly 
  MV BE criterion accounting for the correlation 
  BE  Not BE 
  Incorrect correct Total  Incorrect correct Total 
Intersection of 2 
(1 / 2)CI Univariat
e tests (Bonferoni 
correction) 
Incorrect 3.5 15.56 19.07  11.87 0.91 12.78 
Correct 0.37 80.56 80.93  12.29 74.93 87.22 
Total 3.88 96.12 100  24.16 75.84 100 
         
Intersection of 2 
(1 )CI Univariate 
tests 
 
 
Incorrect 3.23 7.81 11.04  15.84 1.72 17.56 
Correct 0.65 88.31 88.96  8.33 74.11 82.44 
Total 3.88 96.12 100  24.16 75.84 100 
         
MV ignoring 
correlation in rule 
 
 
 
Incorrect 0.9 0.52 1.43  22.66 11.04 33.71 
Correct 2.97 95.6 98.57  1.5 64.79 66.29 
Total 3.88 96.12 100  24.16 75.84 100 
 
5.6. Comparison Between the Three MV PBE criteria 
The power functions of testing for bioequivalence using the three multivariate 
PBE criteria were compared.. Chervenova (2007) linearized the condition of 
bioequivalence, and constructed confidence intervals using properties of the trace. 
Their method cannot be applied to the criteria proposed by Dragalin(2003) and 
Dahman(2009). Dragalin(2003) did not evaluate Dp . To be able to compare the 
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results properly, one standard method was applied to all three criteria. This 
method was to apply the simulation conditions demonstrated earlier to generate 
random samples. For each of those samples the mle‘s of the mean and variance of 
the test and reference were estimated. Each of the PBE criteria was calculated for 
each sample and using bootstrap, the100(1 )th confidence intervals were 
constructed for each criterion. Then probabilities of BE were calculated for each 
scenario.   
Figure 7 presents the comparison of the power functions of the three criteria at 
different sample sizes, and correlations. The plots demonstrate that the power of 
all tests is greater than 90% when the sample size is large (100). The power of Cp 
is lower than 90% with sample size 50. Although Bp does not account for 
correlation, the power function varied by the correlation when the sample size 
was small. This might be just random variations, but more tests are needed to 
verify that. The higher power of Bp is compromised by its higher size which 
exceeds the 0.05 level even when the sample size is only 25. 
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Figure 7 The Power Function by mean of test and sample size (under fixed variance and reference mean) 
 N=25 N=50 N=100 
 
Cp 
   
Dp 
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5.7. Applications 
 
5.7.1  Testing Population Bioequivalence in a parallel design 
Data used was from a study performed by Clayton and Leslie (1981) to study the 
bioequivalence of an enteric-coated erythromycin base (test drug) to the previously available 
reference formulation of erythromycin stearate. After administering the reference or test drug, 
venous blood samples were collected at 0.0, 0.5, 1.0, 2.0, 4.0, 6.0, and 8.0 hours. The data are 
presented in the dissertation appendix F. 
Although this study was intended to follow a two period crossover design, due to non 
randomization and due to the fact that all patients were given the reference drug in the first 
period, and the test drug in the second period it will be treated as a parallel design (Chinchilli & 
Elswick 1997). (this data set was selected because it provides the blood concentrations for all the 
collection times, which will be useful in illustrating the nonlinear model method proposed in the 
next paper.) To illustrate the multivariate method proposed here we first calculated the 
pharmacokinetic parameters. 
Since each subject received both the reference and the treatment drugs, to account for the 
correlations from these repeated measures a mixed effect linear model was selected to fit this 
data. Treatment effect will be treated as a fixed effect. The two multiviarate outcome of interest 
are the Cmax and AUC which are products of the same blood concentration profile for each 
subject. To account for the repeated measure as well as the correlation of the outcomes, a 
multivariate mixed effect model was used and the two outcomes were fit simultaneously. Since 
there were only two periods we modeled the correlation between the two repeated measures as a 
compound symmetry. In studies with more period other structures like autoregressive(1) AR(1) 
or Toepliz are more appropriate and should be considered. To account for the correlation 
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between the outcomes we used an unstructured covariance structure. We also allowed for 
estimating different variance covariance matrices for the two treatment drugs. One of the 
limitations of this experiment was the result of administering the same drug to all patients in each 
period. This results in the redundancy of the period effect and the treatment effect. The period 
effect in properly designed cross-over studies should be modeled as a fixed effect.    
From the blood concentration data we calculated the maxC as the highest concentration 
of the blood concentration time profile, the AUC using the trapezoidal method (Berger RL, 
1996, Gibaldi, 1982). Since these measures are known to be log-normal, they were log-
transformed. Table 9 presents the calculated and transformed data for the 20 subjects under the 
reference and the test drugs. 
Table 9 AUC  and maxC from Clayton and Leslie 
Reference Treatment Test Treatment 
SUBJECT AUC logAUC Cmax logCmax AUC logAUC Cmax logCmax 
1 13.978 2.637 5.350 1.677 10.788 2.378 2.590 0.952 
2 13.810 2.625 4.140 1.421 3.150 1.147 0.920 -0.083 
3 8.865 2.182 3.460 1.241 5.710 1.742 2.600 0.956 
4 9.923 2.295 4.510 1.506 14.033 2.641 3.430 1.233 
5 10.545 2.356 3.700 1.308 5.908 1.776 1.430 0.358 
6 9.855 2.288 4.100 1.411 7.935 2.071 1.990 0.688 
7 23.680 3.165 6.180 1.821 16.295 2.791 3.680 1.303 
8 8.320 2.119 4.070 1.404 6.553 1.880 3.580 1.275 
9 6.353 1.849 2.500 0.916 7.643 2.034 2.120 0.751 
10 12.925 2.559 5.230 1.654 7.658 2.036 1.360 0.307 
11 7.918 2.069 4.240 1.445 2.888 1.060 1.010 0.010 
12 6.700 1.902 2.520 0.924 9.068 2.205 3.110 1.135 
13 10.768 2.377 3.490 1.250 10.743 2.374 2.870 1.054 
14 5.970 1.787 2.100 0.742 4.375 1.476 0.820 -0.198 
15 10.788 2.378 5.180 1.645 9.290 2.229 3.390 1.221 
16 9.345 2.235 3.800 1.335 4.635 1.534 0.920 -0.083 
17 5.850 1.766 1.960 0.673 3.050 1.115 0.850 -0.163 
18 6.158 1.818 2.360 0.859 2.330 0.846 0.490 -0.713 
19 1.650 0.501 0.560 -0.580 5.775 1.754 1.560 0.445 
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20 5.945 1.783 2.060 0.723 3.933 1.369 1.320 0.278 
 
Using the mixed effects model the mle‘s of the means and covariances of both the 
reference and the treatment drugs were estimated. These estimates were  
 
ˆ 0.536maxˆ
ˆ 1.823
TC
T
TAUC


   
    
    
μ and 
ˆ 1.169maxˆ
ˆ 2.134
RC
R
RAUC


   
    
    
μ  
0.2758 0.2556ˆ
0.2556 0.26325
T
 
  
 
Σ  and 
0.28002 0.28035ˆ
0.28035 0.359535
R
 
  
 
Σ  
 
The log transformed maxC and AUC were found to be highly correlated, as expected, 
both in the test group ˆT = 0.88 and in the reference group where ˆR was 0.95.  
The multivariate criterion proposed ( Cˆp ) was calculated from these estimates using equation 
(51). The univariate criterion of PBE for each of AUC and CMax were also calculated according 
to equation (43). Then the bootstrap method was used to determine the upper limits of the 90% 
confidence intervals for the MV criterion and the two univariate criteria. The multivariate PBE 
rule theta which defines the upper boundary were calculated in two ways: i) by ignoring the 
correlations between the PK ( p  =3.49), and ii) by accounting for these correlations ( p  
=4.32). 
Parametric bootstrap was set to generate 2000 samples and calculate the multivariate 
criterion for each sample and then generating the 90% confidence interval of original Cˆp and to 
determine the upper limits of the 90% confidence intervals for the MV criterion and the two 
univariate criteria, these were found as 16.87, 2.32 and 5.30. The qualitative results of these tests 
as bioequivalent or not are performed by comparing the upper limit of the one-sided 95% CI to 
the predetermined acceptance boundary. 
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To compare between the multivariate test and the univariate tests, we used the bootstrap 
samples  to evaluate the probabilities of rejecting bioequivalence using the multivariate test, and 
the univariate tests. Those probabilities are actually the p-values of those tests. We also tested 
bioequivalence using the two univariate test simultaneously under the assumption of 
independence. This is a rectangular test which means that the p-value represents the probability 
of rejecting bioequivalence with respect to AUC and/or Cmax. 
The estimates of the upper limit of the one-sided 95% CI were greater than the upper 
boundaries of the bioequivalence acceptance limits in the multivariate and the two univariate 
cases. So these results show that for this study the two formulations are not bioequivalent using 
either the multivariate or the univariate population bioequivalence testing. It also shows that for 
this specific example accounting for the correlations did not make a difference in the qualitative 
result.  
Table 10 presents the results of the comparison of the tests p-values. Although all tests 
rejected bioequivalence in this study, there are noticeable differences between the p-values of the 
bivariate test p=0.8425 and the intersection of the two univariate tests p=0.5885. the value of the 
multivariate test is larger so it is more conservative in accepting BE the using the univariate test 
separately or simultaneously.   
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Table 10 result of PBE testing of Clayton data 
  p 
Bivariate test with rule theta no corr P(Cp>3.49)  0.9185 
Univariate AUC P(C1>1.74) 0.5430 
Univariate Cmax  P(C2>1.74) 0.0995 
Bivariate test with rule theta with corr P(Cp>4.32) 0.8425 
Assuming independence Intersection of 2 univariate  
1-[P(C1<1.74)* 
P(C2<1.74)] 0.5885 
 
 
 
5.7.2  Testing multivariate PBE in a crossover design: 
 
Twenty eight subjects were recruited in the study, and were given 3 doses of each of the 
two drugs, with a washout period between each of the two sessions. The order in which the two 
drugs were given was selected at random using a block randomization method to ensure the 
balance within each subject. Although there are 20 possible ways to assign three A‘s and three 
B‘s, the random process did not cover all possibilities. 
 At the beginning of each session, baseline data were collected 30 seconds prior to the 
administration of the drug. The pharmacological baseline measurement was supposed to be zero 
if the wash out period was appropriately long enough. Then the drug was administered, and the 
specified pharmacological measurement (level of specific active material in the blood) was 
obtained over several minutes at very short intervals. 
 Each subject was administered one of the two drugs in all six sessions, however due to 
mechanical failure, or lower than qualified measures, some of the sessions were completely 
missing all blood measures. No information about those sessions was provided other than the 
drug given. 
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 From the blood concentration by time data presented in the APPENDIX E, the 
pharmacokinetic PK metrics were calculated. The maximum absorbed blood level of the active 
material ( maxC ) was defined as the highest observed concentration. The time associated with that 
concentration ( maxC ) was considered the maxT . The total absorbed drug was calculated as the 
AUC using the trapezoidal method. Table 11 presents the natural logs of maxC  and AUC for 
each subject in each session of the study. The sequence in the table determines which drug was 
given in each period. 
This study was powered to test the bioequivalence using one outcome at a time. Since we 
are interested in accounting for the correlations between the evaluated outcomes, the multivariate 
mixed model could be applied. We used a bivariate mixed model where the two outcomes 
log(Cmax) and log(AUC) were estimated simultaneously. 
 It also assumes that the correlation is decaying as the periods are further apart. 
Using the estimates of logCmax and logAUC for each of the treatment and the variance 
covariance structures displayed in Table 12, the univariate and multivariate criteria for PBE we 
calculated according to (43) and (51). Using bootstrap method, the upper limit of the 90% 
confidence interval of these criteria were calculated. 
 
The correlations between the logCmax and logAUC were found to be .9 for both the 
treatment and the the test drugs. The PBE criteria were estimated as Cˆp = -0.03132, univariate 
C1 = 0.057199, univariate C2 = -0.06109. The upper limits of the 90% CI were 1.75622, 
1.17345, 0.95773 estimated by the bootstrap were compared to the acceptance boundaries 
2.3103, 1.74483, 1.74483 for the multivariate, the univariate for Cmax and the univariate for the 
AUC respectively. 
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The comparison of the p-values for these tests are presented in Table 13. In this example 
again, all the tests resulted in the same qualitative result that those too drugs are bioequivalent. 
The differences in the p-values suggest the high possibility of getting different qualitative results 
in other samples or examples. The results in Table 13 display that the tests that accounts for the 
correlation between the outcomes has higher probability of rejecting bioequivalence than the test 
that ignore the correlation. 
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Table 11 PM data 
sequence logCmax1 logAUC1 logCmax2 logAUC2 logCmax3 logAUC3 logCmax4 logAUC4 logCmax5 logAUC5 logCmax6 logAUC6 
ABABAB 1.668 5.112 . . . . . . . . . . 
BABABA 2.588 6.073 2.313 5.733 2.152 5.745 2.079 5.671 2.416 5.819 2.163 5.585 
BABBAA 2.632 6.246 2.313 5.896 2.342 5.853 2.603 6.035 2.116 5.701 2.282 5.850 
AABABB 3.025 5.930 2.407 6.004 2.067 5.667 2.001 5.563 2.434 5.839 2.241 5.813 
ABABAB . . . . 2.001 5.608 . . . . . . 
ABBBAA . . 1.131 2.442 . . 1.361 4.210 1.526 4.398 1.386 4.467 
ABBAAB 2.976 6.276 3.077 6.460 2.912 6.455 2.981 6.471 2.815 6.276 2.912 6.449 
BABBAA 1.482 4.417 1.668 4.488 1.411 4.377 2.907 6.159 2.791 5.972 2.653 6.157 
ABAABB . . 2.851 6.125 2.695 5.677 2.398 5.670 2.510 5.849 2.754 5.906 
ABAABB 2.241 5.628 2.262 5.798 2.028 5.592 2.092 5.550 2.175 5.621 2.241 5.800 
BBBAAA 1.932 5.474 1.825 5.433 1.808 5.432 1.792 5.376 2.092 5.730 1.988 5.678 
AABBAB . . . . 1.792 5.103 1.361 4.684 1.335 4.545 1.435 4.623 
ABAABB 1.504 4.465 . . 1.932 4.579 1.411 3.411 1.932 4.719 . . 
BABAAB 1.723 5.394 1.917 5.429 1.902 5.459 2.054 5.484 2.282 5.716 2.079 5.725 
ABBAAB 1.335 4.624 . . 1.686 5.371 2.152 5.594 1.974 5.147 1.361 5.017 
BABBAA 1.740 5.348 1.163 3.984 1.723 4.433 2.425 5.595 1.361 3.671 1.386 4.520 
BABABA 2.493 5.974 2.833 6.279 2.960 6.457 2.741 6.246 3.699 6.395 2.653 6.247 
BAABAB 3.307 6.406 3.343 6.205 2.976 6.211 3.250 6.535 3.195 6.447 3.339 6.093 
BBAAAB 2.251 5.760 2.116 5.697 2.175 5.864 2.028 5.460 1.932 5.642 . . 
ABBAAB 2.734 6.181 2.701 6.198 2.001 5.633 2.588 6.084 2.833 6.444 2.741 6.353 
BBABAA 3.219 6.428 3.091 6.271 3.364 6.479 . . 3.100 6.329 . . 
BABABA 2.610 6.007 2.760 6.154 3.030 6.524 2.728 6.197 . . 3.049 6.660 
BBABAA 2.896 5.933 3.367 6.204 3.144 6.097 2.944 6.055 3.250 6.398 3.127 6.296 
AABABB 2.851 6.393 2.803 6.256 2.827 6.393 . . 2.518 6.145 2.603 6.138 
AABABB 2.342 5.791 2.688 6.351 2.407 6.093 2.868 6.359 3.118 6.838 2.797 6.339 
AABABB 3.025 6.403 3.780 6.887 3.630 7.202 3.170 6.366 3.140 6.440 3.481 6.793 
BBAABA 2.603 5.605 2.617 5.782 2.493 5.711 2.380 5.501 2.493 5.504 2.632 5.781 
ABBABA . . 1.932 5.592 2.067 5.600 2.001 5.615 1.856 5.534 1.723 5.466 
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Table 12 Mean and covariance estimates of PM data using multivariate mixed model  
 ˆ A  ˆB  ˆ A Σ  
ˆ
BΣ  
logCmax 2.2018  2.2891  0.135903 0.175565
0.175565 0.283044
 
 
 
 
0.152862 0.187008
0.187008 0.284740
 
 
 
 
logAUC 5.5115  5.6456  
 
Table 13 Results of test comparison 
  p 
Bivariate test with rule theta 
no corr 
P(Cp>3.49)  0.0005 
Univariate AUC P(C1>1.74) 0.0140 
Univariate Cmax  P(C2>1.74) 0.0070 
Bivariate test with rule theta 
with corr 
P(Cp>2.31) 
0.023 
Assuming independence 
Intersection 
 of 2 univariate  
1-[P(C1<1.74)* P(C2<1.74] 
0. 0209 
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5.8. Conclusion 
In this article the univariate definition of population bioequivalence was extended to account 
for simultaneous multivariate testing of bioequivalence. A new multivariate criterion that is an 
extension to the FDA approved univariate criterion was developed. The statistical properties of 
this criterion in testing for bioequivalence were investigated using a simulation study. It was  
presented that this newly developed and proposed MV criterion could be a reliable aggregate 
measure for bioequivalence with good size and power properties. This study presented the 
importance for accounting for the correlation in defining the acceptable bioequivalence region. 
Further work is required to provide a guideline on how to use the correlation in defining the 
acceptable PBE regions.  
The problem of asymmetry could result in conflicting determinations of BE depending on the 
drug used as a reference. Solutions to this problem need to be investigated. This article did not 
study the multivariate testing using more than two outcomes. This could be a subject for a 
separate study.  There are computational difficulties when attempting  to use more complex 
covariance structures to account for differences in variability between treatment drugs and to 
account for different covariance structures other than compound symmetry and autoregressive(1) 
when using multivariate mixed effect models. The effect of these limitations warrants further 
investigation. Finally, the patterns and effects of the missing observations in these studies on the 
multivariate evaluation of population bioequivalence were not evaluated. 
The methodology developed in this article does not utilize the complete blood concentration 
data collected in bioequivalence studies to generate the blood concentration profiles. This 
method only uses the point estimates of the PKs estimated from the blood concentration profiles 
 104 
 
and assumes they are measured without any error. This assumption is not reliable, so other 
analysis models should be considered to account for the variability of these profiles.  
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6 Testing Population Bioequivalence Using Non Linear Mixed Effects Models  
 
6.1. Introduction 
Bioequivalence testing is an important part of the drug approval process. Companies that 
make generic drugs are required, by the Food and Drug Administration (FDA), to show enough 
evidence that the generic drug is bioequivalent to the originally approved and patented drug. It is 
also required from the original manufacturers when they introduce a new formulation of their 
previously approved drugs. It is assumed that any drugs with the same chemical composition or 
active ingredient will have the same biological effect if they have similar absorption rates, 
blood/serum concentration levels and similar excretion rates. With this assumption the approval 
of generic drugs or new formulations of previously approved drugs does not require the 
extensive testing of toxicity and efficacy that is required for the approval of new drugs.  
The FDA publishes and updates, daily, the ―Approved Drug Products with Therapeutic 
Equivalence Evaluations‖, which is commonly known as the Orange Book. The designation of 
‗therapeutic equivalence‘ indicates that the generic formulation is (among other things) 
bioequivalent to the original (or innovator) formulation and signifies the FDA‘s expectation that 
the formulations are likely to have equivalent clinical effect and no difference in their potential 
for adverse effects. The main criterion for the inclusion of any product is that the product is the 
subject of an application with an effective approval that has not been withdrawn for safety or 
efficacy reasons.  In addition, the Orange Book contains therapeutic equivalence evaluations for 
approved multisource prescription drug products (FDA, 1998). 
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Pharmaceutical equivalence means that two drugs contain the same amounts of the active 
pharmaceutical ingredients in the same dosage and route of administration. Therapeutic 
equivalence requires, in addition to the pharmaceutical equivalence, the two drugs to be 
bioequivalent.  Bioequivalence is defined by FDA in section 505(j)(8)(B) of the Federal food, 
Drug, and Cosmetic Act as: ―the rate and extent of absorption of the drug do not show a 
significant difference from the rate and extent of absorption of the listed drug when administered 
at the same molar dose of the therapeutic ingredient under similar experimental conditions in 
either a single dose or multiple doses‖ or ―the extent of absorption of the drug does not show a 
significant difference from the extent of absorption of the listed drug when administered at the 
same molar dose of the therapeutic ingredient under similar experimental conditions in either a 
single dose or multiple doses and the difference from the listed drug in the rate of absorption of 
the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of 
effective body drug concentrations on chronic use, and is considered medically insignificant for 
the drug.‖(Congress, 2008) 
Bioequivalence studies attempt to gain insight on formulation ―switchability‖ (i.e., the 
ability to substitute one formulation or another without concern of the potential for reduced 
effectiveness or increased probability of adverse effects). A key assumption is that switchability 
may be inferred from plasma concentration vs. time data and metrics reflecting the rate and 
extent of drug absorption. The area under the plasma concentration vs. time curve (AUC) is 
commonly employed as the metric describing the extent of drug absorption, while the maximal 
concentration observed following drug administration (Cmax) is the metric recommended by the 
FDA to evaluate the rate of drug absorption (FDA, 1992).  
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In the July 1992 guidance on Statistical Procedures for Bioequivalence Studies Using a 
Standard Two-Treatment Crossover Design, it was recommended that a standard in vivo BE 
study design be based on the administration of either single or multiple doses of the T and R 
products to healthy subjects on separate occasions, with random assignment to the two possible 
sequences of drug product administration (FDA, 1992). 
In addition to the constants of absorption and elimination, the maximum concentration of 
the drug Cmax, and the total amount of the drug available in the compartment of effect AUC are 
usually used to compare the bioavailability of drugs, and hence to compare their effectiveness. 
6.2. Estimation of PK metrics 
It is widely known that drugs or other chemicals are absorbed, metabolized, and 
eliminated from the body according to specific mechanisms that are peculiar to each drug or 
groups of drugs and its physio-chemical metabolic pathways, and to the anatomical 
compartments it is distributed through. These pharmacological compartments are instantaneously 
well mixed and kinetically homogeneous. These specific mechanisms result in specific 
pharmacological compartmental model. These compartmental models are postulations of how 
the pharmacological system is believed to function. They are composed of finite number of 
components, like one-, two- or higher order- compartmental models. These compartments are 
specifically connected with each other, and each of them has specific input and output routes. 
The absorption of each drug into each of these compartments follows specific models like zero- 
or first-order models. Similarly the excretion of  any drug from any of these compartments has 
its own models and constants. 
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6.2.1 Non-model based estimation 
The metrics used to evaluate the bioequivalence of drugs are usually estimated from the 
blood-concentration-time profiles using non-model or non-compartmental methods. These 
methods do not assume any knowledge of the pharmaceutical models the drug could follow.  
They use algebraic equations to describe the blood-concentration profiles. For example, the AUC 
resultant from a single dose of a drug formulation is commonly assessed with the linear 
trapezoidal method (Berger RL, 1996, Gibaldi, 1982). The area of the trapezoids connecting the 
consecutive time points and their measured blood concentrations are calculated and summed to 
produce the AUC .  The trapezoidal formula used for AUC  is an approximation of the total area 
under the curve. The further the distance between the time points when the blood concentrations 
are measured, the larger the inaccuracy of the calculated AUC . Depending on the original profile 
of blood concentration curve, this could be an underestimation in some cases and an 
overestimation in other cases. 
maxC  is measured as the highest observed concentration. Although this measure 
rarely coincides with the true maxC  
(the estimate is biased downward), this measure is widely 
used in bioequivalence determinations. It is not unusual for plasma concentration profiles that 
reach a peak then the concentration drops, only for the concentration to peak again. The second 
peak may be higher or lower than the first peak. In these situations, the maxC is usually 
estimated as the concentration of the highest peak in profile. However, the first peak may be used 
as the estimate of maxC  when used as a measure of absorption. The maxT  
is defined as the time 
when maxC is observed, and similar to maxC , it is rarely accurate. 
The rate of absorption could be measured in two ways. The first method is based on the 
linear fit of the first few points (at least three points) from beginning of the concentration profile 
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to the first peak. This absorption constant, usually noted as 0k , is calculated as the slope of that 
linear fit. The number of points chosen for this fit is based on the R-squares of the fits.  Other 
methods uses nonlinear models to estimate the absorption rate constant denoted as ak . These 
estimates of the bioequivalence parameters are non-model based calculations and they cannot 
account for the uncertainty in measuring the drug concentration. Alternatively, these parameters 
could also be estimated by fitting mechanistically meaningful non-linear models. 
These non-model based estimates assume that the drug concentration measurements are 
made without errors, hence they ignore the uncertainty of these measurements. 
6.2.2 Model-based estimation 
Pharmacokinetic curves of approved drugs are always studied extensively during and 
after the approval of the drug. In the early phases of drug development these models might not be 
known. However, after the approval of the drug, and before the development of new 
formulations or generic drugs all model characteristics would be studied from which they could 
be well specified and all the characteristics of the plasma-concentration curves could be 
determined and the compartmental models could be defined.  These compartmental models can 
handle non-linearities in the functions of blood concentration with time. They are often used in 
the experimental designs and to estimate the dosing regiments for phase I clinical trials. 
Acquiring this knowledge and the availability of advance analytic software makes it logical to 
use compartmental or model-based methods for estimating the metrics used in evaluating 
bioequivalence. 
Non-linear models have been used in pharmacology to study the pharmacokinetics of 
drugs for a long time. These models could be based on the theoretical compartmental models 
describing the underlying mechanism that produces the data. As a consequence, the non-linear 
 110 
 
model parameters have a more physical interpretation (Adams, 2002). However, these models 
are not generally used in drug testing, except for very limited tasks, like estimating the constants 
of absorption and elimination. Even in situations where non-linear models are used to estimate 
the other PK metrics such as AUC and maxC only point estimates are used in the bioequivalence 
testing. The uncertainties in the estimation are ignored (FDA 1992-2001, Chow SC, Liu JP 
2000).    
We demonstrate in this article that the two steps, namely the estimation of the 
pharmacokinetic measures from the concentration time curves and the subsequent multivariate 
bioequivalence testing with respect to these measures could be combined into one complete 
analysis. The proposed method is easy to implement in part due to the emergence of non-linear 
mixed model methods (Davidian 2003, Galecki 2004) and the subsequent software developments 
(Wolfinger 1999, SAS 2008, R-manual 1996, Pinheiro and Bates 2000).    
Consider the one-compartment pharmacological model that determines the drug 
concentration in the plasma or blood at any time point according to this function: 
 
 
k t k ta e e a
a e
k k D
C e e
Cl k k
   
 
, (52) 
where C is the plasma concentration, D  is the dose, Cl  is the clearance, t is the time of the 
measurement, ka is the constant of absorption, and ke is the constant of elimination.  
These are known as the primary parameters of the blood concentration function. Note that the 
clearance rate of the drug is eCl k V , where V is the volume of the active compartment. The 
area under the curve AUC , could be estimated by integrating the plasma concentration function 
with respect to time of the concentration function in (52). That yields a closed form to estimate 
the AUC as the ratio of the dose ( D ) to the clearance ( Cl ). If one is interested in AUC alone, 
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the function in (52) could be re-parameterized in terms of AUC by substituting AUC  for that 
ratio. That is, the model could be rewritten 
 
 
* k t k ta e e a
a e
AUC k k
C e e
k k
   
 
.     (53) 
Similarly maxC could be calculated by differentiating  (52) with respect to t and equating it to 
zero then solving for maxT  and maxC . This yields  
max max
max
k T k Ta e e a
a e
k k D
C e e
Cl k k
   
 
, 
where maxT is calculated as 
   
 
ln lne a
e a
k k
k k


. The calculations of the PK parameters that are 
usually used as metrics in bioequivalence studies are presented here.  However, all other PK 
parameters could be estimated as functions of the primary parameters of the concentration 
function in (52) and its derivatives. The first order absorption ak which is the rate of absorption, 
and the rate of drug elimination, ek , are both estimated directly from these models.  
 
Theory and algorithms for fitting nonlinear models (NLM) have been extensively 
developed and have been in use for decades (Wolfinger 1999, Davidian 2003, Galecki 2004, 
Adams 2002). However, applications of these in the bioequivalence literature seem limited. 
When the blood concentration data is collected a smoothed profile is drawn to represent the 
estimated function. Many PK measures are actually measured from these non linear fits, which 
are usually done on individual subject basis. However these nonlinear models are not used in 
statistical testing of bioequivalence. Only few attempts to fit nonlinear models and use them in 
testing hypotheses in drug studies could be found in the literature.   
 Pinheiro and Bates (1995) applied a nonlinear mixed effect model on data collected to 
study the drug theophylline. The serum concentrations of the drug were measured in 12 subjects 
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over a 25-hour period after oral administration. They applied the nonlinear modeling on a one 
compartment pharmacological model. They used this methodology for studying the 
pharmacodynamics of theophylline. Pinheiro and Bates (2000) also demonstrated that non-linear 
models, unlike linear models, provide more reliable predictions for responses outside the 
observed range of the data.  
Panhardt (2007) recently used simulation studies on the theophylline data to show that 
nonlinear mixed effect models (NLMEM) could be used in testing pharmacological interactions 
and bioequivalence. They considered a cross-over PK study of a drug that follows a first order 
model. They implemented the same model used by Pinheiro and Bates (1995) to compare 
between two drugs using simulated data based on the theophylline data. They used this 
simulation to test for average bioequivalence. They studied only one outcome. They did not 
apply their methods on any multivariate cases. 
  The literature is really scarce in examples of using the nonlinear models in drug 
bioequivalence testing. Even finding a data set that records all the plasma concentrations and 
time for two groups of drugs is very hard.  
Multivariate testing of multiple outcomes was never tested using the nonlinear models. 
Multivariate bioequivalence testing using these models was also never done. 
 
6.3. Multivariate Analysis of PBE: 
To establish bioequivalence in PK the FDA recommends testing the AUC and Cmax.  It 
has been demonstrated that these two PK metrics are highly correlated. However, most of the 
tests of bioequivalence ignore this correlation and test the two variables separately, often without 
multiple comparisons adjustment. Further, even when multivariate methods are used they are 
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essentially an intersection test of the two individual univariate tests. That is, these tests do not 
account for the correlations.  
The acceptance region of bioequivalence in these tests are rectangular (in the case of 
bivariate) or hyper-rectangular (in the case of multivariate). Munk, and Pflujer  (1999)  argue 
that the convex alternatives of this rectangular region (e.g., ellipsoid) is more appropriate in the 
case of multivariate testing if one wishes to appropriately account for the correlated nature of 
these measure. They also show that the 1   confidence rules for convex alternatives are 
actually / 2 level tests—with applications to the multivariate assessment of bioequivalence. 
They suggest a Hotellings‘ 2T  statistic for multivariate version of the average bioequivalence 
testing.  
We developed a multivariate test for population bioequivalence (in the first paper in 
Ch5), that is based on comparing the upper limit of a  100 1   confidence interval of the PBE 
multivariate criterion C p to a fixed bound p that is defined by the regulators (FDA 1999).  
 
6.4. Statistical Method: 
 
Consider a bioequivalence study comparing a new test drug to a reference drug. In such 
studies, which are usually designed as cross-over studies, each subject receives both treatments, 
and he/she might receive each treatment multiple times. So these correlated repeated measures 
need to be accounted for when estimating the fixed effects.  Suppose, the blood-concentration by 
time profile of the reference drug could be represented by a known non-linear function f linking 
concentrations to sampling times of all the subjects with subject specific PK parameters, such as 
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absorption ( ka ), elimination ( ke )rate constants, and clearance half-life ( Cl ). An example of this 
function is the one compartment model function in (52). 
Suppose several subjects are observed over a time interval at different occasions (of 
periods) on different treatments.  At time point, tijpk , let Cijpk  represent the blood-
concentration  of the 
thk  treatment given to the 
thi  subject at the thj time point, in the thp  
period. Here  i  = 1, 2, …, n, k = T or R,  p= 1, 2, …, P, and j  = 1, 2, …, tipk , for, n subjects, 2 
treatments, P periods and tipk  time points. Assume that the sampling times are fixed and 
identical, for each treatment, period, and for all subjects, as often is the case in cross-over trials. 
Then for all , , ,i j p and k , the time tijpk  could be simplified to t j . Let ipkλ be the vector of the 
PK parameters of the subject i for treatment k in period p. Then the nonlinear model for the 
concentration profile is, 
  ,C f tijpk j ipk ijpk λ , (54) 
where ijpk is the measurement error. It is also assumed that ijpk  are independent of ipkλ , and 
they are normally distributed with mean zero and variance 2
ijpk
 . 
Assume that the parameters ipkλ   are random vectors that could be decomposed for each period 
and treatment as 
 .ipk k p ik   λ μ β γ u  (55) 
where .μ is the overall mean, kβ is the fixed effect of the treatment, pγ is the fixed effect of the 
period, and iku is the random effect of subject i for treatment k , it is also assumed that iku is 
distributed as a multivariate normal with mean zero vector and a variance covariance matrix  
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kΨ . To ensure that the estimates are always positive, ipkλ  elements are the natural logarithms 
of the original PK parameters in the function f. The elements of ipkλ  are  log ipkCl , 
 log aipkk , and  log eipkk . 
The mle‘s of the original PK parameters ka  , ke , and Cl  could be estimated using this 
nonlinear mixed effects model. Since maxC and AUC  or other metrics are functions of these PK 
parameters, then the mle‘s of these metrics for each treatment group could be estimated as 
functions of the mle‘s of the PK. The asymptotic approximation of the variance covariance 
matrices of these metrics could be estimated using the Taylor series expansion theorem. Where 
the second partial  derivatives are derived and the mle‘s are estimated. This method is known as 
the delta method. When closed form derivatives are available, the estimation of the information 
matrix is easy. Otherwise other iterative methods are utilized. 
Using these estimates of the means and variance covariance matrices of the test and the 
reference drugs, the multivariate PBE criterion ( C p  ) that was proposed in (the first paper in 
Ch5) would be estimated. Then the 90% confidence interval could be constructed using the 
parametric bootstrap method as suggested by the FDA and as shown in (our first paper). Two 
thousand samples are randomly generated from a multivariate distribution with means and 
variances equal to the mle‘s obtained from the NLMEM. The upper limit of the resultant 
confidence interval is compared to the predefined limit of bioequivalence   described earlier in 
the first paper in Ch5. Bioequivalence is concluded if the upper limit of the 90% confidence 
interval is smaller than the predefined limit  . 
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6.5. Examples: 
6.5.1 Cross over design 
Twenty eight subjects were recruited in the study, and were given 3 doses of each of the 
two drugs, with a washout period between each of two sessions. The order in which the two 
drugs were given was selected at random using a block randomization method to ensure the 
balance within subjects. Although there are 20 possible ways to assign three A‘s and three B‘s, 
the random process did not cover all possibilities. 
 At the beginning of each session, baseline data were collected 30 seconds prior to the 
administration of the drug. The pharmacological baseline measurement is supposed to be zero if 
the wash out period is long enough. After the drug was administered, the specified 
pharmacological measurement (level of specific active material in the blood) was obtained over 
several minutes at very short intervals. 
 Each subject was administered one of the two drugs in all six sessions, however due to 
mechanical failure, or lower than qualified measures, some of the sessions were completely 
missing all blood measures. The data collected from the subjects are presented in (APPENDIX 
E). Only the first two periods were used in this analysis due to computational issues in proc 
nlmixed in SAS9.2 
The goal was to determine if the two drugs are bioequivalent. The NLMEM presented 
above in equation (55) is a suitable model for this data because the administration was repeated 
in nature on subjects, and due to the missing data in one of the periods for few patients. However 
due to computational limitations the random effects were at the subject level only, and they were 
the same for both treatments. 
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The logarithmic transformations of maxC  and AUC  and their variance covariance 
matrices were estimated for each of the treatment by fitting the model in equation (55) . These 
mle estimates are displayed in Error! Reference source not found.. The univariate and 
multivariate criteria for PBE were calculated according to (43) and (51). Then using the 
bootstrap method, the upper limit of the 90% confidence interval of these criteria were 
calculated. The 95
th
 percentile of the MV criterion was 2.33274, and the univariate 95
th
 
percentile for Cmax was 0.88843, while the 95
th
 percentile for the AUC was 1.39511. 
The multivariate rule   was calculated accounting for and ignoring the correlations 
between the variables in the test ( ˆ 0.6T  ) and reference ( ˆ 0.7R  ) groups. The rule theta 
accounting for these correlations was 2.67, while the upper bound of bioequivalence ignoring the 
correlation was 3.49. 
The p-values for testing for bioequivalence were calculated as the probability of rejecting 
bioequivalence among the bootstrap samples. This probability was calculated as the proportion 
of bootstrap samples that had C p greater than the rule  .  
The upper limits of the confidence intervals are all smaller than the predetermined 
bounds. It is concluded that these two drugs (A and B) are bioequivalent. This conclusion did not 
differ by the method used to test in this example. 
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 Table 14 shows that the probabilities of rejecting bioequivalence. The difference in the 
p-values between the test that used the intersection of the two univariate tests and the MV test 
that accounts for correlation in the rule theta was small. On the other hand, the rectangular test 
differed with the   MV test that ignored the correlation in the rule theta by 10-fold difference. 
 
Table 14 Mean and covariance estimates of PM data using multivariate mixed model 
 
 ˆ A  ˆB  ˆ A Σ  
ˆ
BΣ  
Cross over 
example logCmax 1.9738 1.9904 0.803000 0.427108
0.427108 0.56892
 
 
 
 
0.69168 0.365640
0.36564 0.419672
 
 
 
 
logAUC 6.6503 6.4239 
Parallel 
example logCmax 0.1639 1.0525 0.915564 0.81042
0.81042 2.39928
 
 
 
 
0.292656 0.209664
0.209664 0.770328
 
 
 
 
logAUC 2.259 2.3062 
 
Table 15 result of PBE testing of PM data 
  p 
Bivariate test with rule theta no corr P(Cp>3.49)  0.0035 
Univariate AUC P(C1>1.74) 0.0310 
Univariate Cmax  P(C1>1.74) 0.0045 
Bivariate test with rule theta with corr P(Cp>2.67) 0.0245 
Assuming independence Intersection of 2 univariate  1-P(C1<1.74)* P(C2<1.74 0.0354 
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6.5.2 Parallel design 
We used the data from a study performed by Clayton and Leslie (1981) to study the 
bioequivalence of an enteric-coated erythromycin base (test drug) to the previously available 
reference formulation of erythromycin stearate. Twenty subject received the reference drug, and 
after a washout period each subject received the test drug. After administering the reference or 
test drug, venous blood samples were collected at 0.0, 0.5, 1.0, 2.0, 4.0, 6.0, and 8.0 hours. The 
data is presented in the dissertation APPENDIX F. 
This study was described as a parallel design by (Chinchilli and Elswick 1997) because the 
treatments were not randomly assigned to each period.  However, we have to account for the 
correlated nature of the repeated measures within each subject. The lack of the randomization, 
makes the period effect redundant to the treatment effect, so only the treatment fixed effect 
should be included in the model. The same nonlinear mixed effects model (NLMEM) used in the 
cross over design above (without the period effect) was used to model the one-compartment 
pharmacological model that fits this data. 
 The mle estimates of means and covariance were obtained by fitting this models using 
proc nlmixed in SAS 9.2. These estimates are presented in Table 14.  
 
maxC and AUC were found to be moderately highly correlated, as expected, both in the 
test group ˆT was 0.55,  and in the reference group where ˆR was 0.44. The upper limit of 
bioequivalence,   was defined accordingly as 3.48 not accounting for the correlation and as 2.87 
when accounting for the correlations. The multivariate criterion was calculated from these 
estimates and found to be 7.14. The univariate criterion of PBE for each of AUC and maxC were 
found 4.83 and 2.12 respectively. The upper limits of the 90% confidence intervals constructed 
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by the bootstrap for the MV criterion and the two univariate criteria, these were found as 7.14, 
4.83 and 2.12.  
Qualitatively the conclusion in this example did not differ according to which method 
was used. All the tests rejected bioequivalence by a very high p-value. Table 16 shows that the 
differences in the values of p-values are so subtle.  This might be a reflection to the huge 
differences between the estimates of the means of the reference and they are so big that with any 
test bioequivalence is rejected easily. 
 
Table 16 result of PBE testing of Clayton data using NLMEM 
  p 
Bivariate test with rule theta no corr P(Cp>3.49)  0.9730 
Univariate AUC P(C1>1.74) 0.9635 
Univariate Cmax  P(C1>1.74) 0.6740 
Bivariate test with rule theta with corr P(Cp>2. 55) 0.9910  
Assuming independence Intersection of 2 univariate  
1-[P(C1<1.74)* 
P(C2<1.74)] 0.9881 
 
 
 
6.6. Conclusion  
 
We have discussed in this article the methods and processes of estimating the 
pharmacokinetic metrics used in testing bioequivalence. Although the nonlinear models have 
seen a considerable amount of applications and software development , its use in the field of 
bioequivalence testing is in its infancy. We demonstrated how to apply the nonlinear models in 
estimating and testing for bioequivalence. We presented the importance of multivariate testing 
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for bioequivalence, and we implemented the use of the nonlinear mixed effects models to 
account for correlated data in the bioequivalence studies repeated measure. 
 
We faced several computational limitations in the implementation of these mixed models. 
These are important issues that need to be investigated and studied. As an example of these 
limitations, we were unable to model more than one random effects in the nonlinear models. 
Another example is the convergence issues with higher number of periods in the cross-over 
designs. That forced us to limit the analysis to two periods only. Increasing the number of 
variables fixed or random effects greatly reduces the speed of the computations, and many time 
the estimations fail due to the large number of parameters to estimate. The starting values that 
are required to get good estimates are many times hard to determine, which results in local 
convergences, that are far from the real estimates.  
We did not study the effect of choosing various models of the variance covariance structures 
for the repeated measures. This might affect the estimation of the fixed effects of interest. This 
could be the subject of a future study. 
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7 Summary and Recommendations for Future Work 
 
In this study we extended the definition of the population bioequivalence into the 
multivariate dimension. We derived a criterion that is an actual multivariate extension of the 
univariate PBE approved by the FDA. Using a simulation study we have shown that this 
multivariate criterion has satisfactory properties (size and power) in testing for population 
bioequivalence. 
The simulation study has also shown that this criterion suffers from two problems. The 
first is being asymmetric with respect to the Reference and the Test, where the exchanging the 
reference for the test metrics will result in un-identical results. This problem makes it possible to 
consider drug A bioequivalent to the reference drug B, however drug B is not bioequivalent to 
drug A.  
This problem is not in the multivariate test only. It could be displayed in the univariate 
tests. It is due to the scaling of this criterion by the reference variance, or variance covariance 
matrix in the multivariate case. One may argue that in bioequivalence studies, the reference and 
test formulation cannot be treated equally, and that the test should be proved to be equivalent to 
the reference, and not the other way around. In other words the FDA puts extra burden on the 
generic drug producers to prove bioequivalence of their products to the novel drug.  
For patients, bioequivalent drugs are drugs that could be used interchangeably to 
treatment certain ailments or to alleviate specific symptoms. From this respect, bioequivalence 
should not be different between two drugs depending on which was considered the reference 
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drug. Actually by definition the bioequivalence studies are surrogates for clinical trials in 
evaluating the therapeutic equivalence of the generic drugs to the novel drug.  
The asymmetric property might be especially inconvenient if the equivalence of two 
generic drugs, or two new drugs, is to be evaluated. The KLD method might be a good solution 
for this issue. Testing the merits of this method in studying multivariate population 
bioequivalence might convince the FDA to change its stance of rejecting it. 
. 
Another problem is due to the aggregate nature of this criterion which is a sum of two 
entities. The upper limit of this criterion could be reached by increasing either one of the entities 
while keeping the other as small as possible, or by increasing both entities simultaneously. The 
impact of this is that multivariate bioequivalence could be met even if it is violated at one of the 
univariate tests when the other metric is close to zero. This is a limitation of all aggregate tools. 
That is why the FDA requires that to show univariate population bioequivalence, univariate 
average bioequivalence should be presented. Similarly we might need to show multivariate BE 
after showing univariate population BE. This is an important research question that needs to be 
investigated to try to find measures or methods that have the hierarchical nature of average 
bioequivalence and population bioequivalence. 
The distance approach in evaluating bioequivalence is very intuitive. That‘s why it is 
easy to extend from the average bioequivalence into the population bioequivalence by adding the 
distance between the variances. However, when we looked into the multivariate case of PBE, 
another parameter appears, that is the correlation. It is hard to understand the correlations 
between the reference and between the test drug metrics as part of the distance between the two 
distributions of the reference and the test. That‘s why it is hard to select a meaningful difference 
in the correlations that could affect the bioequivalence. We tested the acceptance regions with 
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and without correlations, but our selection of the correlation to be equal to the estimated 
correlation of the data was arbitrary. Future research might be able to create some guidelines on 
how to define the acceptable differences in correlations. 
We compared between the three PBE criteria. We examined Dragalin‘s criterion of PBE 
that was based on the KLD. This criterion was not accepted by the FDA although it was never 
tested before. The reason for the rejection is related to put the burden on the producer of the test 
drug to prove that it is equivalent to the reference drug. Although this is reasonable in most of 
the cases, there are cases where more than one generic drugs could be compared, and such cases 
require that both drugs be proven equivalent to each other regardless of which one is considered 
the reference. More testing of Dragalins criterion as a true distance measure between any two 
distributions might prove useful in other applications of equivalence testing where no preference 
is given to any distribution.        
We also discussed and demonstrated how nonlinear models are good tools in evaluating 
bioequivalence by showing how to use it in population bioequivalence studies. We demonstrated 
the use of nonlinear mixed effects models in bioequivalence studies. We have shown that the 
development in statistical software had made it much easier to use these complex models in 
estimating the metrics and their variances. However there are still many limitations. For 
example, there is no direct way to implement a specific covariance pattern for repeated 
correlated measure. There is no specific way to have more than one random effect, although in 
some situations it is required to have random effects for different units of analysis.  
We demonstrated the use of the NLMEM on the one-compartment pharmacological 
model. There are much more complex models in pharmacological studies. However, it is well 
known that the nonlinear models are very mechanistic. We could use these models to model 
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almost all intrinsic mechanisms for any pharmaceutical processes, like absorption, elimination, 
effective range, onset of activity, lag of action, etc. Nonlinear models could be used in modeling 
more complex models than the one-compartment model that we demonstrated. It is important to 
test bioequivalence applications using more complex models. 
Bioequivalence problems could be handled by a frequentist or a Bayesian approach, but 
frequentist solutions are more common in the literature and much more often used in practice, 
despite the nice properties of many Bayesian solutions. This may be due in part to the weight of 
regulatory agencies in bioequivalence testing, the most significant application area. There might 
be a regulatory bias towards the frequentist approach, but it is also likely that the level of 
difficulty and the weak understanding of the  Bayesian approach might reducing the use of such 
methods in this field. It would be interesting to approach PBE and it multivariate testing from a 
Bayesian approach.  
The studies in this dissertation were limited to equal size samples of reference and test 
drugs. This might not be realistic in a lot of BE studies. The simulation studies also did not have 
any missing values. The effect of different sample sizes, missing values and dependence between 
the treatments drugs should be tested in future studies. 
 
 
 
.   
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APPENDIX A: Population Bio-Equivalence a distance measure  
 
The population bioequivalence was proposed by [Ref] as a measure of the distance 
between the distribution of the T treatment and the reference R treatment. This distance is scaled 
by the variance of the reference treatment. 
 
   
 
2 2
2
2
E Y Y E Y YT R R R
E Y YR R
            
    
 (56) 
The first term of denominator, and second term of the numerator: 
 
   2 2 22
2 2 2 2 2 22 2
E Y Y EY E Y Y EYR R R RR R
R R R R R R
     
        
     
 (57) 
Note the division by two in the denominator allows for scaling by the reference variance 2R . 
The first term of the numerator: 
 
   
 
 
2 2 22
2 2 2 2 2
2 2 2 2 2
E Y Y EY E Y Y EYT R T RT R
E Y YT RT T R R
T R T RT T R R
   
       
    
  
    
     
 (58) 
Under the assumption of independence between the reference R and Test distributions ( 0   ) 
  2 2 2 2 2E Y YT R T T R R   
     
  
 (59) 
 
 
 134 
 
 
Then the numerator in (56) will reduce to 
 
   
 
 
2 2 2 2 2 2 22 2
2 2 2 22
2 2 2
E Y Y E Y YT R R R T RT T R R R
T RT R T R
T R T R
      
     
   
                 
    
   
 (60) 
Then the univariate population bioequivalence is expressed as: 
 
 2 2 2
2
T R T R
R
   

  
 (61) 
 This was used by Zarifa in testing bioequivalence, by comparing this criterion to a 
predetermined upper limit   
 
 
 
 
   
2 2 2
2
2 2 2 2
2 2 2 2 0
2 2 2 1 0
T R T R
R
T R T R R
T R T R R
T R T R
   


    
    
    
  

   
    
    
 (62) 
The upper limit of the 90% confidence interval for the linearized criterion 
   2 2 2 1T R T R         should be negative to accept bioequivalence. 
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APPENDIX B: Derivation of MV PBE 
 
Derivation of MV PBE 
The univariate population bioequivalence (PBE) criterion is expressed as  
 
   
 
2 2
2
2
E Y Y E Y YT R R R
E Y YR R
            
    
 (63) 
This expression could be rewritten as 
 
 2 2 2
2
T R T R
R
   

  
 (64) 
To develop the equivalent multivariant equivalent for the criterion in 1.1, let TY and RY be p-
variate random variables denoting the test and reference PK metrics. Let‘s assume that TY is 
distributed as a p-variate normal with a mean Tμ  and a variance covariance matrix TΣ . And let 
RY  and RY be two realizations of the p-variate normally distributed random variable with mean 
Rμ  and a variance covariance matrix RΣ . 
Then the multivariate equivalent of the denominator in (63) is   
    2E R R R R R
      
Y Y Y Y Σ  (65) 
Then the multivariate criterion that is equivalent to (63) could be written as:  
        1 1C E Ep T R R T R R R R R R
                 
Y Y Σ Y Y Y Y Σ Y Y  (66) 
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Let  1 2R T R
 Z Σ Y Y ; and let  1 2R R R

 K Σ Y Y , then by substitution with Z  and K in 
(66), the multivariate criterion could be expressed as  
    C E Ep   Z Z K K  (67) 
Note that  
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 
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 
 
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 


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Z Z
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 (68) 
Then the multivariate population bioequivalence criterion could be written as; 
            C trace E E trace E Ep     Σ Z Z Σ K KZ K  (69) 
The expectation of Z is equal to  
 
   
 
 
1 2
1 2
1 2
E E R T R
ER T R
R T R
  
  
    
 
Z Σ Y Y
Σ Y Y
Σ μ μ
 (70) 
So the second term of the right hand side of (69) is  
 
       
   
1 2 1 2
1
E E T R R R T R
T R R T R
    
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Z Z μ μ Σ Σ μ μ
μ μ Σ μ μ
 (71) 
The last term of (69) is zero because, the expectation of K is  
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   
 
 
1 2
1 2
1 2
E E R R R
ER R R
R R R
     
     
 

K Σ Y Y
Σ Y Y
Σ μ μ
0
 (72) 
Note that the covariance of Z is:  
 
 
  
 
    
 
1 2
1 2 1 2
1 2 1 2
1 2 1 2
1 2 1 2 1 2 1 2
Cov
Cov R T R
CovR T R R
Cov CovR T R R
R T R R
R T R R R R

 
  
  
  
    
Σ ZZ
Σ Y Y
Σ Y Y Σ
Σ Y Y Σ
Σ Σ Σ Σ
Σ Σ Σ Σ Σ Σ
 (73) 
Since the last term of the above equation reduces to a pxp identity matrix, then the variance-
covariance matrix of Z  reduces to 1 2 1 2R T R
  Σ Σ Σ I                                                
And the covariance of K  
 
 
  
 
    
 
1 2
1 2 1 2
1 2 1 2
1 2 1 2
2
Cov KK
Cov R R R
CovR R R R
Cov CovR R R R
R R R R

  
   
   
  

Σ
Σ Y Y
Σ Y Y Σ
Σ Y Y Σ
Σ Σ Σ Σ
I
 (74) 
Substituting into (69) and using the cyclical properties of the trace, the multivariate criterion 
could be expressed as 
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           
       
     
1 2 1 2 1 2
1 1
C trace E E trace E Ep Z K
trace traceR T R T R R T R
trace pT R T R R T R
    
       
     
Σ Z Z Σ K K
Σ Σ Σ I μ μ Σ μ μ I
Σ Σ μ μ Σ μ μ
 
So the Multivariate criterion is 
      1 1C trace pp T R T R R T R     Σ Σ μ μ Σ μ μ  (75) 
. 
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APPENDIX C: Distribution of Multivariate PBE criterion 
 
Using a simulation with sample sizes 25, 50, and 100 per treatment group, and with a 
difference between the treatment and reference groups d , as: 0.7, 1, and 1.3. and differences 
between the variances of the treatment and reference groups 2 2
T R
  as: 0.0, 0.02, and 0.04. 
The multivariate criterion was calculated, and its histograms representing its distribution were 
plotted.  
The following two figures show that the distribution of C p get more toward the normal 
as the sample size increases when the variances the variances are between the two treatment 
groups are equal, however this trend is not seen when the variances are between the two 
treatment groups are not equal.  
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N \ d  .7 1 1.3 
25 
   
50 
   
100 
   
Figure 8 Distribution of Cp by sample size and mean diff under independence 
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N \ 2 2
T R
   0 0.02 0.04 
25 
   
50 
   
100 
   
Figure 9 Distribution of Cp by sample size and difference of variances under independence
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APPENDIX D: Graphical presentation of PBE Acceptance regions 
 
To graphically illustrate the ellipsoidal nature of the regions of equivalence developed by 
the test consider the following. Let TX and RX be vectors of random variables representing the 
metrics used in bioequivalence testing.  Let TX be distributed as multivariate normal with mean 
vector Tμ and variance covariance matrix TΣ . Let RX be distributed as multivariate normal 
with mean vector Rμ and variance covariance matrix RΣ . Then bioequivalence acceptance 
region is defined as  
      1 1C trace pp T R T R R T R p      Σ Σ μ μ Σ μ μ  (76) 
Note that this could be reordered as 
      1 1p traceT R R T R p T R     μ μ Σ μ μ Σ Σ  (77) 
The right hand side of this inequality, which is a scalar, does not depend on the means. 
Therefore, the left hand side is a quadratic form in terms of the difference of the mean vectors 
and thus the inequality represents an ellipsoid whose shape is controlled by the variance 
covariance matrices (Johnson and Wichern.xxx). Similary we could construct an ellipsoid based 
on the estimates of the parameters on both LHS and RHS of the equation above such that 
ˆ
95C Cp p .  That is, the ellipsoid formed by the inequality, 
      1 1ˆ ˆ ˆˆ ˆ ˆ ˆ 95C p traceT R R T R p T R     μ μ Σ μ μ Σ Σ . (78) 
Bioequivalence is then pictorially presented if the second ellipsoid (actual data) is totally 
contained within the first ellipsoid defined by the regulators‘ limits. In Figure 10 examples of 
these ellipsoids are presented. The values were chosen to demonstrate, accounting for the 
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correlation between the variables actually changes the acceptance region. This result could be 
vastly different depending on how the correlation is incorporated. For example, the area in the 
figure that is outside the red ellipse (that ignores correlation) is outside the bioequivalence 
acceptance region if we ignore correlation,  however it will be within the bioequivalence region 
if we account for the correlation. 
Figure 10 Acceptance bioequivalence regions 
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Create two data sets 
Test and reference with the following variance and means: 
 
sigmaT sigmaR mubarT mubarR Mubar d 
0.0407217 -0.000756 0.0412375 -0.000168 1.1275743 1.0130981 0.1144762 
-0.000756 0.0448253 -0.000168 0.0410481 1.1182117 0.9863747 0.131837 
 
 
Theta for the bivariate is 3.5, and theta for the univariate is 1.75 
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The point estimates of the PBE criteria 
 
Bivariate  
Cp_Data 
Univariate  
C1_data 
Univariate 
C2_data 
0.8236143 0.3052789 0.5154513 
 
The upper limit of the 95% CI for these found by 2000 bootstraps as 
 
theta Cp_95 C1_95 C2_95 
3.489652 1.313103 0.604775 0.881751 
 
In the same bootstrap, also calculated the upper limit of the quadratic form 
quad_C quad_theta 
1.053592 3.661915 
 
The ellipses of the quadratic term with the following limits were plotted: 
 
 
   1 1ˆ ˆ ˆˆ ˆ ˆ ˆT R R T R p T Rtrace p
              
   1 195ˆ ˆ ˆˆˆ ˆ ˆ ˆT R R T R p T RC trace p
             
 
Then ˆ ˆ&R T  where modified to have a correlation=0.5 and the same variances. 
 
The quadratic forms were plotted again; 
The plot shows that the although the angle changes from 0 to 45, the upper and lower limits do 
not change 
The outer ellipses are from    1 1ˆ ˆ ˆˆ ˆ ˆ ˆT R R T R p T Rtrace p
              
And the inner ellipses are from    1 195ˆ ˆ ˆˆˆ ˆ ˆ ˆT R R T R p T RC trace p
             
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APPENDIX E: PM Data Blood Concentration Curves 
PM Data Blood Concentration Curves 
PM Data 
All data from 1-7 seconds were zeros. 
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Figure 11 Blood conc.by time curves averaged over periods 
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Figure 12 Blood conc curves by treatment and period 
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APPENDIX F: Parallel Design Data 
This data from: 
―Clayton D, Leslie A: The bioavailability of erythromycin stearate vesus enteric-coated 
erythromycin base when taken immediately before and after food. Journal of International 
Medical Research 9:4770-4777, 1981‖ 
Variable name t0 t05 t10 t15 t20 t40 t60 t80 
Concentration @ time 0 30min 60min 90min 2hours 4hours 6hours 8hours 
 
Table 17 Reference Concentrations by subject and time 
SUBJECT Treatment t0 t05 t10 t15 t20 t40 t60 t80 
1 Reference 0 5.00 5.35 4.42 3.13 1.00 0.28 0.12 
2 Reference 0 0.07 2.08 3.42 4.14 2.30 0.52 0.21 
3 Reference 0 1.63 3.46 3.31 2.18 0.66 0.25 0.12 
4 Reference 0 0.62 4.51 3.98 2.67 0.71 0.23 0.15 
5 Reference 0 2.66 3.70 3.34 2.74 0.83 0.23 0.15 
6 Reference 0 0.17 2.62 4.10 3.04 0.88 0.34 0.17 
7 Reference 0 4.12 5.40 6.13 6.18 2.68 1.10 0.57 
8 Reference 0 2.24 4.07 3.11 1.68 0.55 0.16 0.09 
9 Reference 0 1.43 2.50 2.01 1.45 0.49 0.22 0.15 
10 Reference 0 2.63 5.23 3.62 3.34 1.04 0.38 0.17 
11 Reference 0 1.44 4.24 1.84 1.87 0.56 0.28 0.14 
12 Reference 0 2.52 2.25 1.66 1.54 0.48 0.23 0.14 
13 Reference 0 0.09 3.01 3.49 2.93 1.32 0.46 0.25 
14 Reference 0 0.26 2.10 1.96 1.92 0.47 0.19 0.09 
15 Reference 0 0.57 5.18 3.69 3.07 0.77 0.28 0.13 
16 Reference 0 0.65 3.80 3.16 2.08 0.97 0.41 0.18 
17 Reference 0 0.09 1.86 1.96 1.70 0.56 0.26 0.13 
18 Reference 0 1.16 2.36 1.87 1.49 0.54 0.20 0.12 
19 Reference 0 0.11 0.09 0.36 0.56 0.18 0.12 0.07 
20 Reference 0 0.12 1.90 2.06 1.90 0.49 0.21 0.13 
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Table 18 Test concentration by subject and time 
SUBJECT Treatment t0 t05 t10 t15 t20 t40 t60 t80 
21 Test 0 0.10 0.66 1.08 2.59 1.88 1.26 0.35 
22 Test 0 0.12 0.10 0.13 0.10 0.13 0.92 0.75 
23 Test 0 0.24 2.60 2.60 1.48 0.38 0.14 0.10 
24 Test 0 0.10 2.08 3.43 2.87 2.45 1.13 0.48 
25 Test 0 0.13 0.98 0.64 0.69 1.43 0.56 0.19 
26 Test 0 0.16 1.66 1.99 1.52 1.60 0.38 0.17 
27 Test 0 0.53 2.94 2.58 3.68 2.47 1.48 0.77 
28 Test 0 0.11 3.58 2.60 1.79 0.39 0.14 0.11 
29 Test 0 0.13 0.14 0.12 0.15 2.12 1.11 0.80 
30 Test 0 0.10 1.26 0.97 0.69 1.29 1.36 0.33 
31 Test 0 0.10 0.12 0.08 0.07 0.14 1.01 0.35 
32 Test 0 0.07 0.08 0.69 3.11 1.42 0.79 0.34 
33 Test 0 0.13 0.11 0.14 0.13 2.87 1.83 0.99 
34 Test 0 0.12 0.17 0.65 0.82 0.82 0.50 0.24 
35 Test 0 0.14 0.09 0.10 0.10 3.39 0.93 0.36 
36 Test 0 0.13 0.10 0.14 0.12 0.92 0.92 0.62 
37 Test 0 0.10 0.09 0.12 0.14 0.11 0.85 0.80 
38 Test 0 0.13 0.10 0.10 0.10 0.45 0.49 0.16 
39 Test 0 0.08 0.09 0.08 0.12 1.56 0.91 0.56 
40 Test 0 0.08 0.11 1.32 0.67 0.74 0.35 0.16 
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Figure 13 Reference and Test serum concentration profiles 
reference 
 
Test  
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AUC was calculated using the trapezoidal method. CMax was determined as the highest 
observed concentration. 
 
Table 19 AUC and Cmax from non-compartmental methods 
Reference Treatment Test Treatment 
SUBJECT AUC logAUC Cmax logCmax SUBJECT AUC logAUC Cmax logCmax 
1 13.978 2.637 5.350 1.677 21 10.788 2.378 2.590 0.952 
2 13.810 2.625 4.140 1.421 22 3.150 1.147 0.920 -0.083 
3 8.865 2.182 3.460 1.241 23 5.710 1.742 2.600 0.956 
4 9.923 2.295 4.510 1.506 24 14.033 2.641 3.430 1.233 
5 10.545 2.356 3.700 1.308 25 5.908 1.776 1.430 0.358 
6 9.855 2.288 4.100 1.411 26 7.935 2.071 1.990 0.688 
7 23.680 3.165 6.180 1.821 27 16.295 2.791 3.680 1.303 
8 8.320 2.119 4.070 1.404 28 6.553 1.880 3.580 1.275 
9 6.353 1.849 2.500 0.916 29 7.643 2.034 2.120 0.751 
10 12.925 2.559 5.230 1.654 30 7.658 2.036 1.360 0.307 
11 7.918 2.069 4.240 1.445 31 2.888 1.060 1.010 0.010 
12 6.700 1.902 2.520 0.924 32 9.068 2.205 3.110 1.135 
13 10.768 2.377 3.490 1.250 33 10.743 2.374 2.870 1.054 
14 5.970 1.787 2.100 0.742 34 4.375 1.476 0.820 -0.198 
15 10.788 2.378 5.180 1.645 35 9.290 2.229 3.390 1.221 
16 9.345 2.235 3.800 1.335 36 4.635 1.534 0.920 -0.083 
17 5.850 1.766 1.960 0.673 37 3.050 1.115 0.850 -0.163 
18 6.158 1.818 2.360 0.859 38 2.330 0.846 0.490 -0.713 
19 1.650 0.501 0.560 -0.580 39 5.775 1.754 1.560 0.445 
20 5.945 1.783 2.060 0.723 40 3.933 1.369 1.320 0.278 
 
. 
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Figure 14 Raw and Predicted Blood Concentration Profiles of Reference drug 
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Figure 15 Raw and Predicted Blood Concentration Profiles of Test drug 
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Figure 16 Raw and Predicted Blood Concentration Profiles of Reference and Test Drugs 
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APPENDIX G: Confidence intervals of the estimated size in table 1 
Table 20 95% CI of estimates sizes in table 1 
  Cp95<theta Cp95<theta-c 
rhoR rhoT n=25 n=50 n=100 n=25 n=50 n=100 
-0.2 -0.2 
-0.029 , 
0.049 
0 , 0 0 , 0 
-0.032 , 
0.058 
-0.013 , 
0.019 
-0.009 , 
0.036 
 0 0 , 0 
-0.016 , 
0.029 
0 , 0 0 , 0 
-0.016 , 
0.029 
-0.005 , 
0.058 
 0.2 
-0.025 , 
0.039 
0 , 0 0 , 0 
-0.025 , 
0.039 
-0.018 , 
0.045 
0.002 , 0.078 
 0.4 
-0.019 , 
0.026 
0 , 0 
-0.008 , 
0.015 
-0.034 , 
0.067 
-0.018 , 
0.045 
-0.006 , 
0.053 
 0.8 0 , 0 
-0.016 , 
0.029 
-0.01 , 0.03 
-0.035 , 
0.075 
-0.017 , 
0.077 
-0.005 , 
0.058 
0 -0.2 
-0.019 , 
0.026 
-0.018 , 
0.045 
-0.009 , 
0.036 
-0.019 , 
0.026 
-0.018 , 
0.045 
-0.009 , 
0.036 
 0 
-0.019 , 
0.026 
-0.019 , 
0.059 
-0.01 , 0.03 
-0.019 , 
0.026 
-0.019 , 
0.059 
-0.01 , 0.03 
 0.2 
-0.019 , 
0.026 
-0.018 , 
0.045 
-0.002 , 
0.068 
-0.019 , 
0.026 
-0.018 , 
0.045 
-0.002 , 
0.068 
 0.4 0 , 0 
-0.018 , 
0.045 
-0.01 , 0.03 0 , 0 
-0.018 , 
0.045 
-0.01 , 0.03 
 0.8 
-0.029 , 
0.049 
-0.019 , 
0.052 
-0.003 , 
0.063 
-0.029 , 
0.049 
-0.019 , 
0.052 
-0.003 , 
0.063 
0.2 -0.2 
-0.029 , 
0.049 
0 , 0 
-0.009 , 
0.036 
-0.025 , 
0.039 
0 , 0 -0.01 , 0.03 
 0 0 , 0 
-0.012 , 
0.105 
0.011 ,  
0.102 
0 , 0 
-0.019 , 
0.052 
-0.006 , 
0.053 
 0.2 
-0.032 , 
0.058 
-0.018 , 
0.071 
0.005 ,  
0.088 
-0.029 , 
0.049 
-0.018 , 
0.045 
-0.009 , 
0.023 
 0.4 
-0.032 , 
0.058 
-0.012 , 
0.105 
0.025 ,  
0.129 
-0.025 , 
0.039 
-0.018 , 
0.071 
-0.006 , 
0.053 
 0.8 
-0.035 , 
0.135 
-0.002 , 
0.136 
0.075, 
0.212 
-0.036 , 
0.082 
-0.018 , 
0.045 
0.003 , 0.083 
0.4 -0.2 
-0.019 , 
0.026 
0 , 0 -0.01 , 0.03 
-0.019 , 
0.026 
-0.013 , 
0.019 
-0.009 , 
0.036 
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  Cp95<theta Cp95<theta-c 
rhoR rhoT n=25 n=50 n=100 n=25 n=50 n=100 
 0 0 , 0 
-0.016 , 
0.029 
-0.002 , 
0.068 
0 , 0 0 , 0 
-0.007 , 
0.047 
 0.2 
-0.025 , 
0.039 
-0.016 , 
0.083 
0.018 , 0.116 
-0.019 , 
0.026 
-0.019 , 
0.059 
-0.008 , 
0.042 
 0.4 
-0.029 , 
0.049 
-0.012 , 
0.105 
0.064 ,  
0.196 
-0.025 , 
0.039 
-0.018 , 
0.045 
-0.009 , 
0.023 
 0.8 
-0.035 , 
0.141 
0.066, 
0.274 
0.275 , 
0 .465 
-0.029 , 
0.049 
-0.019 , 
0.065 
-0.008 , 
0.042 
0.8 -0.2 0 , 0 0 , 0 0 , 0 
-0.025 , 
0.039 
-0.016 , 
0.083 
-0.002 , 
0.068 
 0 0 , 0 0 , 0 0 , 0 
-0.025 , 
0.039 
-0.018 , 
0.038 
-0.007 , 
0.047 
 0.2 0 , 0 0 , 0 0 , 0 
-0.025 , 
0.039 
-0.018 , 
0.045 
-0.008 , 
0.015 
 0.4 0 , 0 0 , 0 0 , 0 
-0.019 , 
0.026 
-0.016 , 
0.029 
-0.002 , 
0.068 
 0.8 
-0.032 , 
0.058 
0.023, 
0.197 
0.198, 
0.375 
0 , 0 0 , 0 
-0.007 , 
0.047 
.  
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APPENDIX H: Results of Crossover Design mixed model 
Type 3 Tests of Fixed Effects   
Effect Num DF Den DF F Value Pr > F 
outcome 1 38.2 5284.2 <.0001 
sequence 14 13.4 2.26 0.0726 
period 5 104 0.91 0.4807 
Treatment 1 105 5.2 0.0247 
Treatment*outcome 1 92.2 1.6 0.2097 
 
 
Solution for Fixed Effects       
Effect    Estimate 
Standard 
Error DF t Value Pr > |t| 
Intercept    1.9832 0.4428 13 4.48 0.0006 
outcome logAUC   3.3565 0.04935 51.9 68.01 <.0001 
outcome logCmax   0 . . . . 
sequence AABABB   0.8618 0.4899 12.5 1.76 0.103 
sequence AABBAB   -0.4223 0.6364 13.8 -0.66 0.5179 
sequence ABAABB   0.263 0.508 12.7 0.52 0.6136 
sequence ABABAB   0.001884 0.5766 16.4 0 0.9974 
sequence ABBAAB   0.4606 0.506 12.5 0.91 0.3799 
sequence ABBABA   -0.07047 0.627 13.1 -0.11 0.9122 
sequence ABBBAA   -0.6698 0.6278 13.1 -1.07 0.3052 
sequence BAABAB   1.3201 0.6196 12.5 2.13 0.0537 
sequence BABAAB   0.01746 0.6196 12.5 0.03 0.978 
sequence BABABA   0.7231 0.506 12.5 1.43 0.1775 
sequence BABBAA   0.1171 0.5059 12.5 0.23 0.8207 
sequence BBAAAB   0.161 0.627 13.1 0.26 0.8013 
sequence BBAABA   0.6355 0.6196 12.5 1.03 0.3245 
sequence BBABAA   1.1973 0.5389 12.7 2.22 0.0452 
sequence BBBAAA   0 . . . . 
period 1   -0.06025 0.1114 70 -0.54 0.5904 
period 2   0.007936 0.1062 78.4 0.07 0.9406 
period 3   -0.06229 0.09954 90.4 -0.63 0.533 
period 4   0.03087 0.09082 104 0.34 0.7346 
period 5   0.08034 0.07215 111 1.11 0.2679 
period 6   0 . . . . 
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Treatment A  -0.08724 0.04502 110 -1.94 0.0552 
Treatment B  0 . . . . 
Treatment*outcome A logAUC -0.04687 0.0371 92.2 -1.26 0.2097 
Treatment*outcome A logCmax 0 . . . . 
Treatment*outcome B logAUC 0 . . . . 
Treatment*outcome B logCmax 0 . . . . 
         
 
 
Least Squares Means     
Effect trt  Estimate 
Standard  
Error Lower Upper 
Treatment*outcome A logAUC 5.5115 0.1112 5.2814 5.7416 
Treatment*outcome A logCmax 2.2018 0.09974 1.9895 2.4142 
Treatment*outcome B logAUC 5.6456 0.1113 5.4154 5.8758 
Treatment*outcome B logCmax 2.2891 0.09996 2.0764 2.5017 
.
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Table 21 Example of R covariance Matrix for subject 20 Example of the R covariance matrix for 
subject # 20 
0.1531 0.152 0.09697 0.09628 0.06143 0.06099 0.03891 0.03864 0.02465 0.02448 0.01562 0.0155 
0.152 0.2687 0.09628 0.1702 0.06099 0.1078 0.03864 0.06832 0.02448 0.04328 0.0155 0.02742 
0.09697 0.09628 0.1531 0.152 0.09697 0.09628 0.06143 0.06099 0.03891 0.03864 0.02465 0.02448 
0.09628 0.1702 0.152 0.2687 0.09628 0.1702 0.06099 0.1078 0.03864 0.06832 0.02448 0.04328 
0.06143 0.06099 0.09697 0.09628 0.1531 0.152 0.09697 0.09628 0.06143 0.06099 0.03891 0.03864 
0.06099 0.1078 0.09628 0.1702 0.152 0.2687 0.09628 0.1702 0.06099 0.1078 0.03864 0.06832 
0.03891 0.03864 0.06143 0.06099 0.09697 0.09628 0.1531 0.152 0.09697 0.09628 0.06143 0.06099 
0.03864 0.06832 0.06099 0.1078 0.09628 0.1702 0.152 0.2687 0.09628 0.1702 0.06099 0.1078 
0.02465 0.02448 0.03891 0.03864 0.06143 0.06099 0.09697 0.09628 0.1531 0.152 0.09697 0.09628 
0.02448 0.04328 0.03864 0.06832 0.06099 0.1078 0.09628 0.1702 0.152 0.2687 0.09628 0.1702 
0.01562 0.0155 0.02465 0.02448 0.03891 0.03864 0.06143 0.06099 0.09697 0.09628 0.1531 0.152 
0.0155 0.02742 0.02448 0.04328 0.03864 0.06832 0.06099 0.1078 0.09628 0.1702 0.152 0.2687 
.  
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APPENDIX I: Results of Crossover Design NLMEM model 
 
proc nlmixed data=BE.concentrations2 ecov ; 
where period<3; 
a= treatment='A'; 
per=period=2; 
 
dose=1; 
 
      parms beta1=-5 beta2=-2 beta3=0  b1=-1 b2=0 b3=1  s2=57 
            s2b1 =0.03  cb12 =0    s2b2 =0.4  ; 
      cl   = exp(beta1 + b1*a+ u1); 
      ka   = exp(beta2 + b2*a+ u2); 
      ke   = exp(beta3+b3*a+p1*per); 
      pred = dose*ke*ka*(exp(-ke*time)-exp(-ka*time))/cl/(ka-ke); 
      model concentration ~ normal(pred,s2); 
      random u1 u2 ~ normal([0,0],[s2b1,cb12,s2b2]) subject=subject; 
 
  cla   = exp(beta1+ b1);  
       kaa   = exp(beta2+ b2);  
       kea   = exp(beta3+b3);  
 
    kab= exp(beta2); 
    keb= exp(beta3); 
    clb= exp(beta1); 
  estimate 'logCmaxModel a' log(kaa*kea*(exp(-
kea*log(kea/kaa)/(kea-kaa))-exp(-kaa*log(kea/kaa)/(kea-kaa)))/(cla*(kaa-
kea))) ; 
  estimate 'logAUCModel a' log(1/cla)  ; 
  estimate 'logCmaxModel b' log(kab*keb*(exp(-
keb*log(keb/kab)/(keb-kab))-exp(-kab*log(keb/kab)/(keb-kab)))/(clb*(kab-
keb))) ; 
  estimate 'logAUCModel b' log(1/clb)  ; 
 
 predict pred out=predvals; 
 
   run; 
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The NLMIXED Procedure 
Specifications 
Data Set BE.CONCENTRATIONS2 
Dependent Variable concentration 
Distribution for Dependent Variable Normal 
Random Effects u1 u2 
Distribution for Random Effects Normal 
Subject Variable Subject 
Optimization Technique Dual Quasi-Newton 
Integration Method Adaptive Gaussian Quadrature 
 
Parameters 
beta1 beta2 beta3 b1 b2 b3 s2 s2b1 cb12 s2b2 p1 NegLogLike 
-5 -2 0 -1 0 1 57 0.03 0 0.4 1 5407.07691 
 
Iteration History 
Iter   Calls NegLogLike Diff MaxGrad Slope 
1   5 5307.82215 99.25476 156.5468 -4082.82 
2   7 5174.03882 133.7833 68.23715 -83.7382 
80   897 4347.94491 0.000617 0.248288 -0.0006 
81   898 4347.94407 0.000845 0.093543 -0.00168 
82   900 4347.94402 0.000047 0.072078 -0.00004 
 
NOTE: GCONV convergence criterion satisfied. 
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Fit Statistics 
-2 Log Likelihood 8695.9 
AIC (smaller is better) 8717.9 
AICC (smaller is better) 8718.1 
BIC (smaller is better) 8738.0 
 
Parameter Estimates 
Parameter Estimate Standard Error DF t Value Pr > |t| Alpha Lower Upper Gradient 
beta1 -6.4239 0.09766 44 -65.78 <.0001 0.05 -6.6207 -6.2271 0.023142 
beta2 -3.6162 0.1890 44 -19.13 <.0001 0.05 -3.9971 -3.2353 0.019694 
beta3 -3.2253 0.1315 44 -24.53 <.0001 0.05 -3.4903 -2.9603 -0.0112 
b1 -0.2264 0.1125 44 -2.01 0.0503 0.05 -0.4531 0.000261 0.048394 
b2 -0.3056 0.2409 44 -1.27 0.2113 0.05 -0.7910 0.1799 0.042683 
b3 -0.1579 0.1653 44 -0.96 0.3445 0.05 -0.4910 0.1752 0.048333 
s2 13.6338 0.4990 44 27.32 <.0001 0.05 12.6280 14.6396 0.025545 
s2b1 0.08768 0.04568 44 1.92 0.0614 0.05 -0.00438 0.1797 0.044931 
cb12 -0.1306 0.04242 44 -3.08 0.0036 0.05 -0.2161 -0.04515 0.00585 
s2b2 0.3163 0.1401 44 2.26 0.0289 0.05 0.03404 0.5986 -0.07208 
p1 0.05966 0.1311 44 0.45 0.6514 0.05 -0.2047 0.3240 0.038647 
 
Additional Estimates 
Label Estimate Standard Error DF t Value Pr > |t| Alpha Lower Upper 
logCmaxModel a 1.9738 0.1351 44 14.61 <.0001 0.05 1.7015 2.2460 
logAUCModel a 6.6503 0.1137 44 58.48 <.0001 0.05 6.4211 6.8795 
logCmaxModel b 1.9904 0.1254 44 15.87 <.0001 0.05 1.7377 2.2432 
logAUCModel b 6.4239 0.09766 44 65.78 <.0001 0.05 6.2271 6.6207 
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Covariance Matrix of Additional Estimates 
Row Label Cov1  Cov2  Cov3  Cov4  
1 logCmaxModel a 0.01825 0.009707 0.000999 0.001117 
2 logAUCModel a 0.009707 0.01293 0.001121 0.004910 
3 logCmaxModel b 0.000999 0.001121 0.01572 0.008310 
4 logAUCModel b 0.001117 0.004910 0.008310 0.009538 
. 
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APPENDIX J: Asymmetry of PBE 
Table 22 Asymmetric effect of the reference and test correlations on true multivariate PBE criterion Bp’s relation to 0  
R  T  
-0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
-0.2 + + + + + + + + + + + + 
-0.1 + + + + + + + + + + + + 
0 = = = = = = = = = = = = 
0.1 - - - - - - - - - - - - 
0.2 - - - - - - - - - - - - 
0.3 - - - - - - - - - - - - 
0.4 + + - - - - - - - - - - 
0.5 + + + - - - - - - - - - 
0.6 + + + + + - - - - - - - 
0.7 + + + + + + + - - - - - 
0.8 + + + + + + + + + - - - 
0.9 + + + + + + + + + + + - 
: ,  : ,  : ,  0 0 0
 is  under no correlation in both reference and test, 3.48970 0
p p p     
  
     
  
This table was generated by comparing p which is calculated according to the row and column correlation to 0  
 179 
 
It shows that asymmetry with respect to the correlation between the reference and between the 
tests.for example 0.8-0.9 combination is on the other side of than 0.9-0.8 combination. 
 
Table 22 was generated by comparing  which is calculated according to the row and column 
correlation to 0 . If   was greater than 0  a ‗+‘ was entered in the cell. If it was smaller a ‗-‗ is 
entered, and if they were equal an ‗=‘ sign was entered.  The table was color coded according to 
the signs. This displays the asymmetry of  with respect to the correlations between the reference 
and between the tests. For example note the signs of  0.8-0.9 combination, although the 
correlations are both large, and they are close in value, the sign comparing an   to 0  is the 
reverse of the 0.9-0.8 combination. These results agree with Figure 17 and Figure 18 and 
emphasize the importance of investigating how to define BE in terms of the correlation, and the 
need for regulatory guidelines. 
. 
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APPENDIX K: Effect of Reference and Test Correlations on   
Figure 17: Effect of R  and T on the rule   
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Figure 18: Effect of R  and T on the rule   
 
 
. 
 
 182 
 
APPENDIX L: Direct Product AR(1) Covariance Structure  
 
. Due to the limited software ability to choose the covariance structure of Bivariate Mixed 
model in SAS, we selected the Direct product AR(1) structure, which is: 
Direct Product AR(1):  UN@AR(1) 
 
2 3 4 5
2 3 4
2 2 31 21
2 221 2
2 5 2 5
1 1 21 21
5 2 2 5
1 1 21 21
5 2 5
21 21 2 21
5 5 2 2
21 21 2 2
1
1
1
1
1
1
    
   
    
   

     
     
      
     
 
 
 
  
  
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This structure assumes a constant correlation between any two measures taken at consecutive 
periods. 
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APPENDIX M: calculated  ‗s for the three MV PBE criteria 
rhoR rhoT theta Chervo_theta _theta1 _theta2 KLD_theta 
-0.2 -0.2 4.11207 1.74483 1.74483 1.74483 2.76005 
0.0 -0.2 3.48965 1.74483 1.74483 1.74483 2.47663 
0.2 -0.2 3.32471 1.74483 1.74483 1.74483 2.42193 
0.4 -0.2 3.63547 1.74483 1.74483 1.74483 2.60509 
0.6 -0.2 4.80603 1.74483 1.74483 1.74483 3.21815 
0.8 -0.2 9.04981 1.74483 1.74483 1.74483 5.36781 
-0.2 0.0 4.23707 1.74483 1.74483 1.74483 2.61508 
0.0 0.0 3.48965 1.74483 1.74483 1.74483 2.24138 
0.2 0.0 3.19971 1.74483 1.74483 1.74483 2.09641 
0.4 0.0 3.34975 1.74483 1.74483 1.74483 2.17143 
0.6 0.0 4.24353 1.74483 1.74483 1.74483 2.61832 
0.8 0.0 7.71647 1.74483 1.74483 1.74483 4.35479 
-0.2 0.2 4.36207 1.74483 1.74483 1.74483 2.59482 
0.0 0.2 3.48965 1.74483 1.74483 1.74483 2.13084 
0.2 0.2 3.07471 1.74483 1.74483 1.74483 1.89559 
0.4 0.2 3.06404 1.74483 1.74483 1.74483 1.86248 
0.6 0.2 3.68103 1.74483 1.74483 1.74483 2.14320 
0.8 0.2 6.38314 1.74483 1.74483 1.74483 3.46647 
-0.2 0.4 4.48707 1.74483 1.74483 1.74483 2.69345 
0.0 0.4 3.48965 1.74483 1.74483 1.74483 2.13125 
0.2 0.4 2.94971 1.74483 1.74483 1.74483 1.79779 
0.4 0.4 2.77832 1.74483 1.74483 1.74483 1.64860 
0.6 0.4 3.11853 1.74483 1.74483 1.74483 1.75522 
0.8 0.4 5.04981 1.74483 1.74483 1.74483 2.65736 
-0.2 0.6 4.61207 1.74483 1.74483 1.74483 2.99138 
0.0 0.6 3.48965 1.74483 1.74483 1.74483 2.30517 
0.2 0.6 2.82471 1.74483 1.74483 1.74483 1.84770 
0.4 0.6 2.49261 1.74483 1.74483 1.74483 1.55665 
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rhoR rhoT theta Chervo_theta _theta1 _theta2 KLD_theta 
0.6 0.6 2.55603 1.74483 1.74483 1.74483 1.46336 
0.8 0.6 3.71647 1.74483 1.74483 1.74483 1.91858 
-0.2 0.8 4.73707 1.74483 1.74483 1.74483 3.97773 
0.0 0.8 3.48965 1.74483 1.74483 1.74483 3.05772 
0.2 0.8 2.69971 1.74483 1.74483 1.74483 2.36646 
0.4 0.8 2.20689 1.74483 1.74483 1.74483 1.82375 
0.6 0.8 1.99353 1.74483 1.74483 1.74483 1.42078 
0.8 0.8 2.38314 1.74483 1.74483 1.74483 1.31928 
 
Figure 19 The upper limit of each of PBE criteria as a function of the correlation 
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